<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>S‐adenosyl methionine (SAMe) for depression in adults - Galizia, I - 2016 | Cochrane Library</title> <meta content="S‐adenosyl methionine (SAMe) for depression in adults - Galizia, I - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011286.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="S‐adenosyl methionine (SAMe) for depression in adults - Galizia, I - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011286.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011286.pub2" name="dc.identifier" scheme="DOI"/> <meta content="S‐adenosyl methionine (SAMe) for depression in adults" name="citation_title"/> <meta content="Ilaria Galizia" name="citation_author"/> <meta content="Lucio Oldani" name="citation_author"/> <meta content="Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico" name="citation_author_institution"/> <meta content="Karine Macritchie" name="citation_author"/> <meta content="King's College" name="citation_author_institution"/> <meta content="karine.macritchie@googlemail.com" name="citation_author_email"/> <meta content="Erica Amari" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Dominic Dougall" name="citation_author"/> <meta content="East London NHS Foundation Trust" name="citation_author_institution"/> <meta content="Tessa N Jones" name="citation_author"/> <meta content="Central and North West London NHS Foundation Trust" name="citation_author_institution"/> <meta content="Raymond W Lam" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Guido Jacopo Massei" name="citation_author"/> <meta content="Lakshmi N Yatham" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Allan H Young" name="citation_author"/> <meta content="Institute of Psychiatry, King's College London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011286.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011286.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011286.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011286.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidepressive Agents [*therapeutic use]; Citalopram [therapeutic use]; Depression [*drug therapy]; Imipramine [therapeutic use]; Randomized Controlled Trials as Topic; S-Adenosylmethionine [*therapeutic use]; Selective Serotonin Reuptake Inhibitors [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011286.pub2&amp;doi=10.1002/14651858.CD011286.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WcPhDegp";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011286\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011286\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ja","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011286.pub2",title:"S\\u2010adenosyl methionine (SAMe) for depression in adults",firstPublishedDate:"Oct 10, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011286.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011286.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011286.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011286.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011286.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011286.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011286.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011286.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011286.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011286.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7748 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011286.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0182"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0076"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-sec-0176"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/appendices#CD011286-sec-0189"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/table_n/CD011286StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/table_n/CD011286StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">S‐adenosyl methionine (SAMe) for depression in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0002">Ilaria Galizia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0003">Lucio Oldani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Karine Macritchie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0005">Erica Amari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0006">Dominic Dougall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0007">Tessa N Jones</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0008">Raymond W Lam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0009">Guido Jacopo Massei</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0010">Lakshmi N Yatham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information#CD011286-cr-0011">Allan H Young</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information/en#CD011286-sec-0194">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011286.pub2">https://doi.org/10.1002/14651858.CD011286.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011286-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011286-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011286-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011286-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011286-abs-0002">日本語</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011286-abs-0001" lang="en"> <section id="CD011286-sec-0001"> <h3 class="title" id="CD011286-sec-0001">Background</h3> <p>Depression is a recurrent illness with high rates of chronicity, treatment‐resistance and significant economic impact. There is evidence in the literature that S‐adenosyl methionine (SAMe), a naturally occurring compound in the human body, has antidepressant efficacy. This product may be an important addition to the armamentarium of antidepressant agents. </p> </section> <section id="CD011286-sec-0002"> <h3 class="title" id="CD011286-sec-0002">Objectives</h3> <p>To assess the effects of SAMe in comparison with placebo or antidepressants for the treatment of depression in adults. </p> </section> <section id="CD011286-sec-0003"> <h3 class="title" id="CD011286-sec-0003">Search methods</h3> <p>We searched the Cochrane Common Mental Disorders Group's Specialised Register (CCMDCTR Studies and Reference Register), MEDLINE, EMBASE, PsycINFO, international trial registers ClinicalTrials.gov and the World Health Organization trials portal (ICTRP). We checked reference lists, performed handsearching and contacted experts in the field. The CCMDCTR literature search was last updated on 5 February 2016. </p> </section> <section id="CD011286-sec-0004"> <h3 class="title" id="CD011286-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing SAMe with placebo or antidepressants in adults with a diagnosis of major depression. </p> </section> <section id="CD011286-sec-0005"> <h3 class="title" id="CD011286-sec-0005">Data collection and analysis</h3> <p>Two authors independently performed extraction of data and assessment of risk of bias. We contacted trialists of included studies for additional information. </p> </section> <section id="CD011286-sec-0006"> <h3 class="title" id="CD011286-sec-0006">Main results</h3> <p>This systematic review included eight trials comparing SAMe with either placebo, imipramine, desipramine or escitalopram. We accepted trials that used SAMe as monotherapy or as add‐on therapy to selective serotonin reuptake inhibitors (SSRIs), and we accepted both oral and parenteral administration. The review involved 934 adults, of both sexes, from inpatient and outpatient settings. </p> <p>The trials were at low risk of reporting bias. We judged the risk of selection, performance, detection and attrition bias as unclear or low, and one study was at high risk of attrition bias. </p> <p>There was no strong evidence of a difference in terms of change in depressive symptoms from baseline to end of treatment between SAMe and placebo as monotherapy (standardised mean difference (SMD) ‐0.54, 95% confidence interval (CI) ‐1.54 to 0.46; P = 0.29; 142 participants; 2 studies; very low quality evidence). There was also no strong evidence of a difference in terms of drop‐out rates due to any reason between SAMe and placebo, when used as monotherapy (risk ratio (RR) 0.88, 95% CI 0.61 to 1.29; P = 0.52; 142 participants; 2 studies; low quality evidence). </p> <p>Low quality evidence showed that the change in depressive symptoms from baseline to end of treatment was similar between SAMe and imipramine, both as monotherapy (SMD ‐0.04, 95% CI ‐0.34 to 0.27; P = 0.82; 619 participants; 4 studies). There was also no strong evidence of a difference between SAMe and a tricyclic antidepressant in terms of drop‐outs due to any reason (RR 0.61, 95% CI 0.28 to 1.31; P = 0.2; 78 participants; 3 studies; very low quality evidence). </p> <p>There was little evidence of a difference in terms of change in depressive symptoms from baseline to end of treatment between SAMe and escitalopram, both as monotherapy (MD 0.12, 95% CI ‐2.75 to 2.99; P = 0.93; 129 participants; 1 study; low quality evidence). There was no strong evidence of a difference between SAMe and escitalopram in terms of drop‐outs due to any reason (RR 0.81, 95% CI 0.57 to 1.16; P = 0.26; 129 participants; 1 study; low quality evidence). </p> <p>There was low quality evidence that SAMe is superior to placebo as add‐on to SSRIs in terms of change in depressive symptoms from baseline to end of treatment (MD ‐3.90, 95% CI ‐6.93 to ‐0.87; P = 0.01; 73 participants; 1 study). There was no strong evidence of a difference between SAMe and placebo as adjunctive therapy to an SSRI in terms of drop‐outs due to any reason (RR 0.70, 95% CI 0.31 to 1.56; P = 0.38; 73 participants; 1 study; very low quality evidence). </p> <p>For all comparisons, secondary outcome measures of response and remission rates were consistent with these primary outcome measures. </p> <p>With regard to all extractable measures of the acceptability of SAMe, the quality of the evidence was low to very low. SAMe was not different from placebo and established antidepressants. The exception was that compared to imipramine, fewer participants experienced troublesome adverse effects when treated with parenteral SAMe. </p> <p>The specific adverse effects were not detailed in most of the included studies. There were two reports of mania/hypomania recorded for 441 participants in the SAMe arm. </p> </section> <section id="CD011286-sec-0007"> <h3 class="title" id="CD011286-sec-0007">Authors' conclusions</h3> <p>Given the absence of high quality evidence and the inability to draw firm conclusions based on that evidence, the use of SAMe for the treatment of depression in adults should be investigated further. Future trials should be in the form of large randomised controlled clinical trials of high methodological quality, with particular attention given to randomisation, allocation concealment, blinding and the handling of missing data. Comparator antidepressants from all classes should be used. Adverse events should be detailed for each participant, bearing in mind that induction of mania is of particular interest. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011286-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011286-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011286-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011286-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011286-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011286-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011286-abs-0004" lang="en"> <h3>S‐adenosyl methionine for depression in adults</h3> <p><b>Description of the illness</b> </p> <p>Depression is a common, recurrent mood disorder. Usually, affected people experience symptoms such as low mood and a loss of interest or pleasure. People with depression also often experience some of the following symptoms: weight loss or gain; a decrease or increase in appetite, insomnia or hypersomnia; restlessness or fatigue as well as excessive guilt; feelings of worthlessness, poor concentration and indecisiveness; recurrent thoughts of death and suicidal thoughts. The medicines most often used in the treatment of depression are antidepressants. </p> <p><b>Description of the medicine</b> </p> <p>S‐adenosyl methionine (often referred to as SAMe) is naturally present in the human body and there is evidence that it is effective as an antidepressant. SAMe has been marketed in some European countries since the mid‐1980s for the treatment of depression and for other medical conditions such as osteoarthritis (joint disease that causes joint pain and stiffness), fibromyalgia (widespread pain and stiffness), liver disease and migraine headaches. However, SAMe is not formally approved in the UK for the treatment of depression, and in the USA it is classified only as a dietary supplement. </p> <p><b>Aim of the review</b> </p> <p>Given the extent of the burden of depression, the high rates of chronicity and the high number of people who do not respond to the conventional treatments, there is an urgent need to examine alternative medications. In this review, we investigated the effectiveness of SAMe in the treatment of depression. </p> <p><b>Results</b> </p> <p>We searched scientific databases for all randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) in adults with a diagnosis of major depression, where SAMe was compared to either placebo (a pretend treatment) or other antidepressant medicines (e.g. imipramine and escitalopram) carried out before February 2016. </p> <p>We included eight studies involving 934 people in this review. There was no strong evidence of a difference in effectiveness between SAMe and imipramine or escitalopram when used alone. It was superior to placebo when used in combination with selective serotonin reuptake inhibitor antidepressants, but this evidence was of low quality. There was no significant difference in terms of effectiveness between SAMe and placebo alone, but again this evidence was of very low quality. The acceptability of SAMe did not differ from that of antidepressants or placebo. The exception was that fewer participants experienced side effects when treated with SAMe compared with imipramine. Though, the quality of the evidence for acceptability of SAMe was of low quality. </p> <p>Limitations of this review were that not all the relevant data could be obtained despite efforts to contact the authors and some of the included studies were of low quality. </p> <p><b>What should happen next</b> </p> <p>It is not possible to draw any firm conclusions from this review and the evidence included is of limited quality. There is a need to investigate the efficacy and acceptability of SAMe for the treatment of depression in adults further in larger and better planned trials. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011286-sec-0182" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011286-sec-0182"></div> <h3 class="title" id="CD011286-sec-0183">Implications for practice</h3> <section id="CD011286-sec-0183"> <p>Given the absence of high quality evidence and the inconsistency of our findings, we are unable to draw firm conclusions about the use of S‐adenosyl methionine (SAMe) for the treatment of depression in adults. It should be investigated further by additional larger high quality randomised controlled trials. </p> <p>There were two reports of mania/hypomania in a review of 441 participants in the SAMe arm. Although this adverse effect was not commonly found in our analysis, it is an important factor to be considered in clinical settings. </p> </section> <h3 class="title" id="CD011286-sec-0184">Implications for research</h3> <section id="CD011286-sec-0184"> <p>Further research of high methodological quality is required to establish the efficacy and acceptability of SAMe confidently. Double‐blind randomised controlled trials should be conducted. Specific attention should be paid to the process of randomisation, allocation concealment, blinding and handling of missing data. </p> <p>In addition, the following methodological issues should be considered.</p> <p> <ol id="CD011286-list-0013"> <li> <p>The population studied. Future studies should include people with a diagnosis of major depression of both sexes; aged 18 years and over; of all ethnicities; and in inpatient, outpatient and primary care settings. Data from particular subgroups of participants with major depression, such as those with psychotic features, mixed features, anxiety symptoms, treatment resistance or atypical depression should be analysed separately. </p> </li> <li> <p>The nature of the intervention. SAMe should be studied in monotherapy and as an adjunctive therapy to antidepressant medication. A dose of 800 mg/day to 1600 mg/day for oral administration and 200 mg/day to 400 mg/day for parenteral administration should be used. There is little available information about the comparability of oral and parenteral doses of SAMe. Clearly, it would be important to establish this in studies where oral and parenteral SAMe are directly compared. Because SAMe is best absorbed on an empty stomach, it should be administered 30 to 60 minutes before meals or two hours after meals; future studies should instruct the participants and monitor for compliance with these instructions. In addition, as the stability of different formulae and of the tablets varies, in future studies the formulation of SAMe should be reported in detail. Trials should also be of at least eight weeks' duration. Comparison interventions should include placebo and alternative antidepressants or adjunctive agents from all classes. The antidepressants tested should not be limited to TCAs and SSRI. </p> </li> <li> <p>Relevant outcome measures. Detailed and complete information should be provided on depression rating scale scores, remission and response rates, drop‐outs with the reasons why and accounts of specific adverse events. It would be desirable if these were documented for each participant. Reports of mania and hypomania are important, particularly with regard to the safety of prescribing this treatment in people with depression at high risk of later developing a bipolar illness. Hyperhomocysteinaemia is also of interest. It would be worthwhile to investigate specific adverse effects that can limit the participants' compliance, such as sexual adverse effects and weight gain; SAMe could potentially have an advantage with regard to adverse effects that are commonly caused by recognised antidepressants. Outcome measures of relevance to participants and their carers should also be included. Further, there could be a gender effect with regard to response to SAMe; this has been reported previously (<a href="./references#CD011286-bbs2-0110" title="SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Sarris 2015a</a>), and may have been a possible explanation for the heterogeneity between the <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> and <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> studies. Therefore, it would be interesting to conduct analyses by the subgroup gender in order to investigate a possible gender effect. </p> </li> <li> <p>Data on the comparative costs of treatment should be included in future studies, to allow economic analyses. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011286-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011286-sec-0022"></div> <div class="table" id="CD011286-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> SAMe as monotherapy </p> <p><b>Comparison:</b> placebo as monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo as monotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe as monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative SMD indicates greater improvement in the SAMe group<br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe groups was<br/> <b>0.54 standard deviations greater</b> (1.54 lower to 0.46 higher) indicating more improvement. However, this was not statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.54 (95% CI ‐1.54 to 0.46)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> <br/> (0.61 to 1.29) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (22 to 47) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.77</b> <br/> (0.51 to 6.13) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 100</b> <br/> (11 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants achieving remission</b> <br/> Depression rating scale score within the normal range at the end of the study </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.69</b> <br/> (0.85 to 3.36) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> <br/> (14 to 56) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of inconsistency caused by high level of heterogeneity (I<sup>2</sup> = 72%; P = 0.06), related to the different duration of the trials and sample size (3 weeks, 18 participants for <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; 12 weeks, 124 participants for <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>).<br/> <sup>2</sup> downgraded one point because of imprecision caused by small sample size, fewer than 400.<br/> <sup>3</sup> downgraded one point because of imprecision caused by a 95% confidence interval that included no effect and the upper and lower confidence limit crosses an effect size of 0.5 in either direction.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300.<br/> <sup>5</sup> downgraded one point because of imprecision caused by a 95% confidence interval that includes both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%).<br/> <sup>6</sup> The two studies showed a non‐significant heterogeneity (I<sup>2</sup> = 49%; P = 0.16). This was due to the <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> study where the number of responder was bigger in the SAMe arm than the placebo arm, but it was not statistically significant (RR 4.80, 95% CI 0.72 to 32.15; P = 0.11). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011286-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to tricyclic antidepressant agent as monotherapy for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine compared to tricyclic antidepressant agent as monotherapy for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> SAMe as monotherapy </p> <p><b>Comparison:</b> TCA as monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe vs. TCA as monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative SMD indicates greater improvement in the SAMe group<br/> Follow‐up: 2 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe group was<br/> <b>0.04 standard deviations greater</b> (0.34 lower to 0.27 higher), indicating more improvement. However, this was not statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.04 (95% CI ‐0.34 to 0.27)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 2 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.61</b> <br/> (0.28 to 1.31) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>78<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 100</b> <br/> (9 to 44) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 100</b> <br/> (7 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 2 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.14</b> <br/> (0.83 to 1.56) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very</b> </p> <p><b>low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 100</b> <br/> (42 to 79) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 100</b> <br/> (28 to 54) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportions of participants achieving remission</b> <br/> Depression rating scale score within the normal range at the end of the study </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> <br/> Follow‐up: 4 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.68</b> <br/> (0.52 to 0.88) </p> <p>statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>604<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> <br/> (25 to 43) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (24 to 41) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SMD:</b> standardised mean difference; <b>TCA:</b> tricyclic antidepressant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; three studies were at unclear risk of selection, performance, detection and attrition bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>).<br/> <sup>2</sup> downgraded one point because of inconsistency caused by significant heterogeneity between the studies (I<sup>2</sup> = 57%; P = 0.07). It was due to one study that favoured SAMe over the active antidepressant (imipramine) (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>). The different result of the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study could be due to its shorter duration (two weeks) and to the fact that the therapeutic actions of imipramine usually are not immediate, but often delayed by two to four weeks. This could suggest a more rapid onset of action of the SAMe. Also, the doses and routes of administration of SAMe among the studies were heterogeneous. However, when subgroup analysis was conducted separating data regarding oral and parenteral administration of SAMe, the outcome was not affected.<br/> <sup>3</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study was at high risk of attrition bias and at unclear risk of selection bias; the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study was at unclear risk of selection, performance, detection and attrition bias.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300.<br/> <sup>5</sup> downgraded one point because of imprecision caused by a 95% confidence interval that includes both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%).<br/> <sup>6</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study was at high risk of attrition bias and at unclear risk of selection bias; two studies were at unclear risk of selection, performance, detection and attrition bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>).<br/> <sup>7</sup> downgraded one point because of inconsistency caused by significant heterogeneity among the studies (I<sup>2</sup> = 58%, P = 0.07). It could be caused by the different durations of the treatment. Then, the studies differed in terms of antidepressants compared to the intervention, but it did not explain the heterogeneity. Also, the doses and routes of administration of SAMe among the studies were heterogeneous. However, when we conducted subgroup analysis separating data regarding oral and parenteral administration of SAMe, the outcome was not affected.<br/> <sup>8</sup> downgraded one point because of risk of bias: the three studies were at unclear risk of selection, performance, detection and attrition bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>).<br/> <sup>9</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study was at unclear risk of selection, performance, detection and attrition bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011286-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to SSRI antidepressant agent as monotherapy for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine compared to SSRI antidepressant agent as monotherapy for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> SAMe as monotherapy </p> <p><b>Comparison:</b> SSRI antidepressant agent as monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe vs. SSRI antidepressant agent as monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative MD indicates greater improvement in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe group was<br/> <b>0.12 standard deviations lower</b> (2.75 lower to 2.99 higher), indicating less improvement. However, this was not statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.12 (95% CI ‐2.75 to 2.99)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/> (0.57 to 1.16) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (31 to 62) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (31 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.66 to 1.7) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> <br/> (22 to 58) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> <br/> (22 to 58) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportions of participants achieving remission</b> <br/> depression rating scale score within the normal range at the end of the study </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.58 to 1.77) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> <br/> (16 to 49) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> <br/> (16 to 49) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SSRI:</b> selective serotonin reuptake inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of imprecision caused by small sample size, fewer than 400.<br/> <sup>2</sup> downgraded one point because of imprecision caused by a 95% confidence interval that included no effect and the upper and lower confidence limit crossed an effect size of 0.5 in either direction.<br/> <sup>3</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a 95% confidence interval that includes both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011286-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">S‐adenosyl methionine as adjunctive treatment compared to placebo as add‐on to SSRI for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine as adjunctive treatment compared to placebo as add‐on for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> SAMe as adjunctive treatment to SSRI<br/> <b>Comparison:</b> placebo as adjunctive treatment to SSRI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo as add‐on</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe as adjunctive treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative MD indicates greater improvement in the SAMe group<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe group was<br/> <b>3.9 greater</b> (6.93 to 0.87 lower), indicating more improvement. This was statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.90 (‐6.93 to ‐0.87)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.7</b> <br/> (0.31 to 1.56) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> <br/> (9 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment. </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.62</b> <br/> (1.17 to 5.83) </p> <p>statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 100</b> <br/> (21 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants achieving remission</b> <br/> depression rating scale score within the normal range at the end of the study. </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.05</b> <br/> (1.11 to 8.39) </p> <p>statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> <br/> (13 to 99) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SSRI:</b> selective serotonin reuptake inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of imprecision caused by small sample size, fewer than 400.<br/> <sup>2</sup> downgraded one point because of indirectness caused by a population restricted to SSRI non‐responders<br/> <sup>3</sup> downgraded one point because of imprecision caused by a 95% confidence interval that included both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011286-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011286-sec-0023"></div> <section id="CD011286-sec-0024"> <h3 class="title" id="CD011286-sec-0024">Description of the condition</h3> <p>Depression is a common recurrent illness with high rates of chronicity. It ranks first among mental illnesses in the causes of worldwide disability (<a href="./references#CD011286-bbs2-0095" title="MurrayCJL , LopezAD . Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet1997;349(9063):1436‐42. ">Murray 1997</a>). The main symptoms of depression are low mood and a loss of interest or pleasure. Physical symptoms include weight loss or gain, a decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation and fatigue. Psychological symptoms such as excessive guilt, feelings of worthlessness, poor concentration and indecisiveness occur. Recurrent thoughts of death and suicidal thoughts and actions may also feature (<a href="./references#CD011286-bbs2-0047" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV). Washington DC: American Psychiatric Association, 1994. ">APA 1994</a>). Anxiety is common in depression (<a href="./references#CD011286-bbs2-0073" title="FawcettJ , KravitzHM . Anxiety syndromes and their relationship to depressive illness. Journal of Clinical Psychiatry1983;44(8, Pt2):8‐11. ">Fawcett 1983</a>), and its presence detrimentally affects the treatment outcome (<a href="./references#CD011286-bbs2-0077" title="GoldbergD , FawcettJ . The importance of anxiety in both major depression and bipolar disorder. Depression and Anxiety2012;29(6):471‐8. ">Goldberg 2012</a>). In cases of severe depression, mood‐congruent psychotic symptoms such as hallucinations and delusions may develop. </p> <p>Atypical depression may be a distinct subtype of depression. Its atypical symptoms include reactivity of mood, increased sleep and increased appetite. This type of depression may preferentially respond to one particular class of antidepressants, monoamine oxidase inhibitors (MAOIs) (<a href="./references#CD011286-bbs2-0083" title="HenkelV , MergiR , AllgaierAK , KohnenR , MöllerHJ , HegeriU . Treatment of depression with atypical features: a meta‐analytic approach. Psychiatry Research2006;141:89‐101. ">Henkel 2006</a>). </p> <p>Treatment‐resistant depression is a significant problem, with a 12‐month prevalence of 2% to 3% (<a href="./references#CD011286-bbs2-0096" title="NemeroffCB . Prevalence and management of treatment‐resistant depression. Journal of Clinical Psychiatry2007;68 Suppl 8:17‐25. ">Nemeroff 2007</a>). Treatment resistance has been defined as occurring when "at least two trials with antidepressants from different pharmacologic classes (adequate in terms of dosage, duration, and compliance) fail to produce a significant clinical improvement" (<a href="./references#CD011286-bbs2-0053" title="BerlimMT , TureckiG . Definition, assessment, and staging of treatment‐resistant refractory major depression: a review of current concepts and methods. Canadian Journal of Psychiatry2007;52:46‐54. ">Berlim 2007</a>). </p> <p>Depression has significant economic impact. It is associated with significant occupational underperformance and low earnings. It is also associated with an increased risk of chronic physical illnesses, early mortality and suicide (<a href="./references#CD011286-bbs2-0086" title="KesslerRC . The costs of depression. Psychiatric Clinics of North America2012;35(1):1‐14. [DOI: 10.1016/j.psc.2011.11.005] ">Kessler 2012</a>). In the USA, the economic cost of depression was USD 83 billion in 2000; USD 26 billion were direct medical costs, USD 5.4 billion were suicide‐related mortality costs and USD 51.5 billion were workplace costs (<a href="./references#CD011286-bbs2-0078" title="GreenbergPE , KesslerRC , BirnbaumHG , LeongSA , LoweSW , BerglundPA , et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry2003;64(12):1465‐75. ">Greenberg 2003</a>). In Europe, the total annual cost of depression in 2004 was EUR 118 billion, approximately 1% of the gross domestic product. Direct costs corresponded to EUR 22 billion for outpatient care, EUR 10 billion for hospitalisation, while indirect costs due to morbidity and mortality were EUR 76 billion (<a href="./references#CD011286-bbs2-0113" title="SobockiP , JönssonB , AngstJ , RehnbergC . Cost of depression in Europe. Journal of Mental Health Policy and Economics2006;9(2):87‐98. ">Sobocki 2006</a>). The total cost of services for depression in England in 2007 was estimated to be GBP 1.7 billion; lost employment brought the total cost to GBP 7.5 billion. The projection is that in 2026 the costs will increase to GBP 3 billion for total cost of services and GBP 12.2 billion for lost employment (<a href="./references#CD011286-bbs2-0087" title="McCroneP , DhanasiriS , PateA , KnappM , Lawton‐SmithS . Paying the Price. The Cost of Mental Health Care in England to 2026. London: The King's Fund, 2008. ">King's Fund 2008</a>). </p> </section> <section id="CD011286-sec-0025"> <h3 class="title" id="CD011286-sec-0025">Description of the intervention</h3> <p>Currently the various major US and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualising the treatment plan, preparing the person for potential long‐term treatment, providing measurement‐based care and treating to remission. With regard to mild depression, some, but not all, guidelines suggest that it may resolve with exercise or watchful waiting, but psychotherapy or antidepressants could be used if initial efforts fail. First‐line treatment recommendations for moderate major depressive disorder include antidepressant monotherapy, psychotherapy and the combination of both (<a href="./references#CD011286-bbs2-0066" title="DavidsonJR . Major depressive disorder treatment guidelines in America and Europe. Journal of Clinical Psychiatry2010;71 Suppl E1:e04. [DOI: 10.4088/JCP.9058se1c.04gry] ">Davidson 2010</a>). In contrast, a combination of depression‐focused psychotherapy and pharmacotherapy is considered a useful treatment choice for people with severe or chronic forms of depression (<a href="./references#CD011286-bbs2-0049" title="American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition. 2010. ">APA 2010</a>). With regard to drugs, normally a selective serotonin reuptake inhibitor (SSRI) is chosen because of its favourable risk‐benefit ratio. In the case of people with depression who have not responded to a first SSRI antidepressant after six to eight weeks of adequate treatment, switching to an alternative antidepressant may be considered. Initially, this may be a different SSRI or a better‐tolerated newer‐generation antidepressant. Subsequently, an antidepressant of a different pharmacological class may be chosen, although this may be less well tolerated, for example venlafaxine, a tricyclic antidepressant (TCA) or an MAOI (<a href="./references#CD011286-bbs2-0097" title="National Institute for Health and Care Excellence. Depression in adults. The treatment and management of depression in adults. NICE clinical guideline 90October 2009. ">NICE 2009</a>). </p> <p>S‐Adenosyl methionine (SAMe) was originally discovered in Italy in 1952 (<a href="./references#CD011286-bbs2-0059" title="CantoniGL . The nature of the active methyl donor formed enzymatically from L‐methionine and adenosine triphosphate. Journal of the American Chemical Society1952;74(11):2942‐3. ">Cantoni 1952</a>), where it is commonly used in clinical practice. SAMe has been marketed in some European countries since the mid‐1980s for the treatment of depression and for other medical conditions such as osteoarthritis, fibromyalgia, liver disease and migraine headaches (<a href="./references#CD011286-bbs2-0062" title="ChavezM . SAMe: S‐Adenosylmethionine. American Journal of Health‐System Pharmacy2000;57(2):119‐23. ">Chavez 2000</a>; <a href="./references#CD011286-bbs2-0070" title="DiRoccoA , RogersJD , BrownR , WernerP , BottiglieriT . S‐Adenosyl methionine improves depression in patients with Parkinson's disease in an open‐label clinical trial. Movement Disorders2000;15 (6):1225‐9. ">Di Rocco 2000</a>; <a href="./references#CD011286-bbs2-0101" title="PapakostasGI , AlpertJE , FavaM . S‐adenosyl methionine in the treatment of depression: a comprehensive review of the literature. Current Psychiatry Reports2003;5:460‐6. ">Papakostas 2003</a>; <a href="./references#CD011286-bbs2-0111" title="ShippyRA , MendezD , JonesK , CergnulI , KarpiakSE . S‐adenosylmethionine (SAM‐e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry2004;4:38. ">Shippy 2004</a>). However, SAMe is not formally approved in the UK for the treatment of depression. In the USA, it has not been classified as a drug but is available as a non‐prescription (over‐the‐counter) dietary supplement under the Dietary Health and Supplement Act of 1999 (<a href="./references#CD011286-bbs2-0101" title="PapakostasGI , AlpertJE , FavaM . S‐adenosyl methionine in the treatment of depression: a comprehensive review of the literature. Current Psychiatry Reports2003;5:460‐6. ">Papakostas 2003</a>). </p> <p>SAMe occurs naturally in the human body. It may be synthesised from adenosine triphosphate and the alpha‐amino acid methionine. Cantoni discovered it to be an active cofactor in biological methylation reactions (<a href="./references#CD011286-bbs2-0088" title="KresgeN , TaborH , SimoniRD , HillRL . An escape from Italy, the discovery of S‐adenosylmethionine, and the biosynthesis of creatine by Giulio L. Cantoni. Journal of Biological Chemistry2005;280:e35. ">Kresge 2005</a>). As a physiological donor of methyl groups, it is involved in many cellular functions including the synthesis and metabolism of neurotransmitters (<a href="./references#CD011286-bbs2-0080" title="GörenJL , StollAL , DamicoKE , SarmientoIA , CohenBM . Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy2004;24(11):1501‐7. ">Gören 2004</a>), and its potential epigenetic effects have been highlighted (<a href="./references#CD011286-bbs2-0115" title="SugdenC . One‐carbon metabolism in psychiatric illness. Nutrition Research Reviews2006;19:117‐36. ">Sugden 2006</a>). </p> <p>Recommended daily doses of SAMe range from 200 mg to 1600 mg taken in divided doses, depending upon the condition for which it is being taken and its severity, and upon the route of administration (<a href="./references#CD011286-bbs2-0062" title="ChavezM . SAMe: S‐Adenosylmethionine. American Journal of Health‐System Pharmacy2000;57(2):119‐23. ">Chavez 2000</a>; <a href="./references#CD011286-bbs2-0067" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5) :1172S‐6S. ">Delle Chiaie 2002</a>; <a href="./references#CD011286-bbs2-0094" title="MorelliV , ZoorobRJ . Alternative therapies: Part I. Depression, diabetes, obesity. American Family Physician2000;62(5):1051‐60. ">Morelli 2000</a>). Exogenous, orally administered SAMe has a short half‐life, undergoing first‐pass effects and rapid metabolism. However, oral doses of SAMe at 1600 mg/day are significantly bioavailable and non‐toxic (<a href="./references#CD011286-bbs2-0080" title="GörenJL , StollAL , DamicoKE , SarmientoIA , CohenBM . Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy2004;24(11):1501‐7. ">Gören 2004</a>). Because SAMe is best absorbed on an empty stomach, it should be administered 30 to 60 minutes before meals or two hours after meals; people should be instructed to adhere strictly to these directions. It may also be administered parenterally, using intramuscular or intravenous routes (<a href="./references#CD011286-bbs2-0118" title="WilliamsAL , GirardC , JuiD , SabinaA , KatzDl . S‐adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and Investigative Medicine2005;28:132‐9. ">Williams 2005</a>).  </p> <p>With regard to possible adverse effects, SAMe is reported to induce mania in some cases (<a href="./references#CD011286-bbs2-0060" title="CarneyMW , CharyTK , BottiglieriT , ReynoldsEH . The switch mechanism and the bipolar/unipolar dichotomy. British Journal of Psychiatry1989;154:48‐51. ">Carney 1989</a>; <a href="./references#CD011286-bbs2-0089" title="LipinskiJF , CohenBM , FrankenburgF , TohenM , WaternauxC , AltesmanR , JonesB . Open trial of S‐adenosylmethionine for treatment of depression. American Journal of Psychiatry1984;141:448‐50. ">Lipinski 1984</a>). In one open study, nine of 11 people with bipolar disorder experienced a switch to an 'elevated mood state' (hypomania, mania or euphoria) (<a href="./references#CD011286-bbs2-0060" title="CarneyMW , CharyTK , BottiglieriT , ReynoldsEH . The switch mechanism and the bipolar/unipolar dichotomy. British Journal of Psychiatry1989;154:48‐51. ">Carney 1989</a>). Reports of induced mania and hypomania were found even in cases with no prior suggestion of bipolar disorder (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>). A transient mixed manic episode with suicidal ideation was reported in a person with no previous psychiatric history on SAMe; recovery followed discontinuation (<a href="./references#CD011286-bbs2-0080" title="GörenJL , StollAL , DamicoKE , SarmientoIA , CohenBM . Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy2004;24(11):1501‐7. ">Gören 2004</a>). These findings must be interpreted with caution as bipolar II disorder (diagnosed by the presence of a hypomanic episode) is sometimes misdiagnosed as major depressive disorder when hypomanic episodes are overlooked. </p> <p>There is a theoretical possibility of hyperhomocysteinaemia, a condition associated with cardiac and renal complications in the long term. However, in their four‐week study of SAMe treatment of healthy participants, <a href="./references#CD011286-bbs2-0080" title="GörenJL , StollAL , DamicoKE , SarmientoIA , CohenBM . Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy2004;24(11):1501‐7. ">Gören 2004</a> found no elevation in homocysteine levels. Mild gastrointestinal disturbance and headache have been reported (<a href="./references#CD011286-bbs2-0080" title="GörenJL , StollAL , DamicoKE , SarmientoIA , CohenBM . Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy2004;24(11):1501‐7. ">Gören 2004</a>; <a href="./references#CD011286-bbs2-0089" title="LipinskiJF , CohenBM , FrankenburgF , TohenM , WaternauxC , AltesmanR , JonesB . Open trial of S‐adenosylmethionine for treatment of depression. American Journal of Psychiatry1984;141:448‐50. ">Lipinski 1984</a>). One Cochrane review on SAMe in the treatment of alcoholic liver disease found no significant increase in adverse or serious adverse effects (<a href="./references#CD011286-bbs2-0105" title="RambaldiA , GluudC . S‐adenosyl‐L‐methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD002235.pub2] ">Rambaldi 2006</a>). </p> <p>The cost of SAMe seems comparable in different countries. In the USA, one local national chain sells 36 SAMe 400 mg tablets for USD 42.99 (<a href="./references#CD011286-bbs2-0064" title="Craig NelsonJ . S‐Adenosyl Methionine (SAMe) augmentation in major depressive disorder. American Journal of Psychiatry2010;167:889‐91. [10.1176/appi.ajp.2010.10040627] ">Craig Nelson 2010</a>). In Italy, the price of 20 SAMe 400 mg tablets amounts to EUR 25.63, whereas in the UK, one local national chain sells 30 SAMe 400 mg tablets for GBP 26.71. The mean cost per tablet in these three countries is EUR 1.08. In some countries such as Italy, Germany and Russia, pharmaceutical grade SAMe is available on physician prescription only. As of 2016, the cheapest antidepressant drugs available in the UK are fluoxetine and citalopram with an approximately comparable price, the net price of a 30‐capsules pack of fluoxetine 20 mg is GBP 1.11, the net price of a 28‐tablet pack of citalopram 20 mg is GBP 1.02 (<a href="./references#CD011286-bbs2-0055" title="Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary. London: British Medical Association, September 2016. ">BNF 2016</a>). Although SAMe seems more expensive, considering its adverse‐effect profile and its rapidity of onset of the antidepressant effect, it may have a specific impact on the use of resources in terms of drug acquisition, treatment duration and dosage, inpatient and outpatient care, treatment of adverse events, management of people who discontinue therapy and time off work. </p> </section> <section id="CD011286-sec-0026"> <h3 class="title" id="CD011286-sec-0026">How the intervention might work</h3> <p>The mechanism of any antidepressant effect of SAMe is unclear. It may enhance the activity of the monoamine systems strongly associated with the aetiology and treatment of depression. Animal studies demonstrated an association between SAMe treatment and increased brain concentrations of noradrenaline (norepinephrine) and serotonin (5‐HT) (<a href="./references#CD011286-bbs2-0042" title="AlgeriS , CattoE , CurcioM , PonziF , StamentinoliG . Changes in rat brain noradrenaline and serotonin after administration of S‐adenosylmethionine. In: ZappiaV , UsdinE , SalvatoreF editor(s). Biochemical and Pharmacological Roles of Adenosylmethionine and the Central Nervous System. New York: Permagon Press, 1979:81‐7. ">Algeri 1979</a>; <a href="./references#CD011286-bbs2-0065" title="CurcioM , CattoE , StramentinoliG , AlgeriS . Effect of S‐adenosyl‐L‐methionine on serotonin metabolism in rat brain. Progress in Neuro‐Psychopharmacology1978;2(1):65‐71. ">Curcio 1978</a>; <a href="./references#CD011286-bbs2-0098" title="Otero‐LosadoME , RubioMC . Acute effects of S‐adenosylmethionine on catecholaminergic central function. European Journal of Pharmacology1989;163:353‐6. ">Otero‐Losado 1989a</a>; <a href="./references#CD011286-bbs2-0099" title="Otero‐LosadoME , RubioMC . Acute changes in 5HT metabolism after S‐adenosylmethionine administration. General Pharmacology1989;20:403‐6. ">Otero‐Losado 1989b</a>). In humans, treatment is reported to increase cerebrospinal fluid concentrations of 5‐hydroxyindole acetic acid (the main metabolite of serotonin) (<a href="./references#CD011286-bbs2-0010" title="AgnoliA , AndreoliV , CasacchiaM , CerboR . Effect of S‐adenosyl‐l‐methionine (SAMe) upon depressive symptoms. Journal of Psychiatric Research1976;13(1):43‐54. ">Agnoli 1976</a>). In addition, through stimulation of phospholipid methylation, SAMe may increase the fluidity of cell membranes that is linked to an increase in β‐adrenoreceptor and muscarinic (M1) receptor density (<a href="./references#CD011286-bbs2-0056" title="BottiglieriT . S‐adenosyl‐L‐methionine (SAMe): from the bench to the bedside ‐ molecular basis of a pleiotrophic molecule. American Journal of Clinical Nutrition2002;78:1151S‐7S. ">Bottiglieri 2002</a>). Further, SAMe may influence the expression of key genes in the brain affecting behaviour, memory, learning and cognition (<a href="./references#CD011286-bbs2-0115" title="SugdenC . One‐carbon metabolism in psychiatric illness. Nutrition Research Reviews2006;19:117‐36. ">Sugden 2006</a>). </p> </section> <section id="CD011286-sec-0027"> <h3 class="title" id="CD011286-sec-0027">Why it is important to do this review</h3> <p>Given the extent of the burden of depression, the prevalence of treatment resistance described above, and the substantial economic cost associated with ineffective depression management compared with successfully treated depression (<a href="./references#CD011286-bbs2-0058" title="ByfordS , BarrettB , DespiégelN , WadeA . Impact of treatment success on health service use and cost in depression: longitudinal database analysis. Pharmacoeconomics2011;29(2):157‐70. [DOI: 10.2165/11537360‐000000000‐00000] ">Byford 2011</a>), there is an urgent need to examine less well recognised approaches to its pharmacological management. SAMe may be an important addition to the armamentarium of antidepressant agents. There is evidence that SAMe has antidepressant efficacy. Existing meta‐analyses of randomised controlled trials (RCT) of SAMe in depression have shown superior efficacy to placebo and efficacy equivalent to TCAs (<a href="./references#CD011286-bbs2-0057" title="BressaGM . S‐adenosyl‐l‐methionine (SAMe) as antidepressant: meta‐analysis of clinical studies. Acta Neurologica Scandinavica. Supplementum1994;154:7‐14. ">Bressa 1994</a>; <a href="./references#CD011286-bbs2-0118" title="WilliamsAL , GirardC , JuiD , SabinaA , KatzDl . S‐adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and Investigative Medicine2005;28:132‐9. ">Williams 2005</a>), a long‐established category of antidepressant (<a href="./references#CD011286-bbs2-0050" title="ArrollB , ElleyCR , FishmanT , Goodyear‐SmithFA , KenealyT , BlashkiG , et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007954] ">Arroll 2009</a>). In addition, SAMe is well established and widely used in some countries, such as Italy. Despite the clear need for new treatments for depression and the apparent evidence for its efficacy, SAMe is not formally approved or widely used as an antidepressant treatment in many countries. It is imperative that the potential role of this agent in depression should be rigorously examined. Further, it is important to consider whether use of SAMe is advantageous in the management of depression given the incremental costs (resource use) and benefits (effects) that may be associated with the intervention. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011286-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011286-sec-0028"></div> <p>To assess the effects of SAMe in comparison with placebo or antidepressants for the treatment of depression in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011286-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011286-sec-0029"></div> <section id="CD011286-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011286-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included RCTs and considered published and unpublished trials.</p> <p>We included cross‐over trials in the review; however, as SAMe treatment may have a lasting effect on depressive symptoms, we only included data from the first phase of cross‐over studies. </p> <p>We planned to include cluster RCTs, with assessment of their potential for unit of analysis errors (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). However, we found no studies of this design. </p> <p>We planned to include full economic evaluations, cost analyses and comparative resource utilisation studies conducted in the context of an RCT. However, we identified no trials providing economic analyses. </p> </section> <section id="CD011286-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD011286-sec-0033"> <h5 class="title">Participant characteristics</h5> <p>Men and women aged from 18 to 80 years.</p> </section> <section id="CD011286-sec-0034"> <h5 class="title">Diagnosis</h5> <p>Participants with a diagnosis of major depression, with or without psychotic symptoms, according to Diagnostic and Statistical Manual of Mental Disorders (DSM)‐III/II‐R (<a href="./references#CD011286-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980. ">APA 1980</a>), DSM‐IV/IV‐TR (<a href="./references#CD011286-bbs2-0046" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980. ">APA 1980</a>; <a href="./references#CD011286-bbs2-0048" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000. ">APA 2000</a>), or International Classification of Diseases (ICD)‐9, ICD‐10 (<a href="./references#CD011286-bbs2-0116" title="World Health Organization. Mental disorders: glossary and guide to their classification in accordance with the ninth revision of the International Classification of Diseases. Geneva: WHO, 1978. ">WHO 1978</a>; <a href="./references#CD011286-bbs2-0117" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD‐10). Geneva: World Health Organization, 1992. ">WHO 1992</a>). </p> </section> <section id="CD011286-sec-0035"> <h5 class="title">Subset data</h5> <p>We included trials examining a particular subgroup of participants with major depression in the meta‐analysis, such as people with psychotic features, anxiety symptoms, treatment resistance or atypical depression. We also analysed these subgroups separately. </p> </section> <section id="CD011286-sec-0036"> <h5 class="title">Comorbidities</h5> <p>We excluded participants with bipolar depression or schizoaffective disorder. Where studies used heterogeneous groups of participants, we excluded these data unless data from those participants with 'unipolar' depression could be extracted separately. If there was any doubt regarding the diagnosis of participants, we approached the authors to obtain clarification. We excluded cyclothymia and dysthymia. </p> <p>We excluded people with DSM‐IV Axis I and II and physical comorbidities.</p> </section> </section> <section id="CD011286-sec-0037"> <h4 class="title">Types of interventions</h4> <section id="CD011286-sec-0038"> <h5 class="title">Experimental intervention</h5> <p>S‐adenosyl methionine (SAMe) as monotherapy or as an adjunct.</p> </section> <section id="CD011286-sec-0039"> <h5 class="title">Comparator intervention</h5> <p> <ol id="CD011286-list-0001"> <li> <p>Placebo.</p> </li> <li> <p>Alternative pharmacological treatment, limited to antidepressants.</p> </li> </ol> </p> <p>We organised antidepressants into classes for the purposes of this review, as follows.</p> <p> <ol id="CD011286-list-0002"> <li> <p>Tricyclic antidepressants (TCAs): amitriptyline, imipramine, trimipramine, doxepin, desipramine, protriptyline, nortriptyline, clomipramine, dothiepin, lofepramine. </p> </li> <li> <p>Heterocyclic antidepressants: mianserin, trazodone, amoxapine, maprotiline.</p> </li> <li> <p>Selective serotonin reuptake inhibitors (SSRIs): fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram, escitalopram. </p> </li> <li> <p>Monoamine oxidase inhibitors (MAOIs), irreversible: phenelzine, tranylcypromine, isocarboxazid; reversible: brofaramine, moclobemide, tyrima. </p> </li> <li> <p>Other antidepressants, noradrenaline reuptake inhibitors (NARIs): reboxetine, atomoxetine; noradrenaline‐dopamine reuptake inhibitors (NDRIs): amineptine, bupropion; serotonin‐noradrenaline reuptake inhibitors (SNRIs): venlafaxine, milnacipram, duloxetine; noradrenergic and specific serotonergic antidepressants (NASSAs): mirtazapine; serotonin antagonist and reuptake inhibitor (SARIs): trazodone; unclassified: agomelatine, vilazodone. </p> </li> </ol> </p> <p>Acute treatment was treatment instituted specifically to alleviate symptoms of an existing episode of depression. We considered trials in which SAMe was used as an adjunctive treatment separately. </p> <p>When trials combined acute treatment and maintenance phases, we analysed acute treatment data separately. When this was not possible, we excluded the study from the review. We excluded studies with treatment durations of less than one week. We excluded discontinuation trials in which participants received SAMe prior to randomisation. </p> </section> </section> <section id="CD011286-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD011286-sec-0041"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0042"> <h6 class="title">Efficacy</h6> <p>1. *Change in mean scores from baseline to end of treatment on the depression rating scale used, such as the Hamilton Depression Rating Scale (HAM‐D; <a href="./references#CD011286-bbs2-0081" title="HamiltonM . A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry1960;23:56‐62. ">Hamilton 1960</a>) and the Montgomery‐Åsberg Depression Rating Scale (MADRS; <a href="./references#CD011286-bbs2-0093" title="MontgomerySA , ÅsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>). </p> </section> <section id="CD011286-sec-0043"> <h6 class="title">Acceptability</h6> <p>2. *Participants dropping out of treatment during study period for any reason.</p> <p>3. Participants dropping out of the treatment during study period because of adverse effects. </p> </section> </section> <section id="CD011286-sec-0044"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0045"> <h6 class="title">Efficacy</h6> <p>4. *Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment. </p> <p>5. *Remission, defined as a depression rating scale score within normal range at end of the study. </p> <p>We used data according to the definitions of the trialists (documented in the 'Outcomes' section of the <a href="#CD011286-sec-0077">Description of studies</a>). The definitions were overall homogeneous. </p> </section> <section id="CD011286-sec-0046"> <h6 class="title">Acceptability</h6> <p>6. *Participants experiencing troublesome adverse effects of any nature.</p> <p>7. Specific adverse effects: mania or hypomania, headache, diarrhoea, flatulence, nausea, hyperhomocysteinaemia, emergent suicidal ideation or behaviours, completed suicide and attempted suicide, mortality excluding suicide, and verdicts of undetermined death and mortality due to iatrogenic causes; the numbers of participants experiencing these adverse events were presented in tabular form. </p> <p>8. Participants dropping out for any reasons other than adverse effects.</p> <p>*Outcomes to be reported in the 'Summary of findings' tables.</p> </section> <section id="CD011286-sec-0047"> <h6 class="title">Economic data</h6> <p> <ol id="CD011286-list-0003"> <li> <p>Mean total direct medical cost per participant, including medication costs, consultant fees and inpatient treatment costs. </p> </li> <li> <p>Direct resources use associated with complications of treatment.</p> </li> <li> <p>Time to onset of antidepressant effect measured as change in depression score (days).</p> </li> <li> <p>Time to return to work (days).</p> </li> <li> <p>Incremental cost per disability‐adjusted life year (DALY).</p> </li> </ol> </p> </section> <section id="CD011286-sec-0048"> <h6 class="title">Timing of outcome assessment</h6> <p>Outcomes were categorised as short‐term (up to six months from the beginning of treatment), medium‐term (six to 12 months) or long‐term (longer than 12 months). We considered the short‐term as our primary time point. </p> </section> <section id="CD011286-sec-0049"> <h6 class="title">Hierarchy of outcome measures</h6> <p>If data on more than one efficacy of treatment measure were provided for a trial, we extracted the data according to the following hierarchy. </p> <p> <ol id="CD011286-list-0004"> <li> <p>HAM‐D.</p> </li> <li> <p>MADRS.</p> </li> <li> <p>Other outcome measure of efficacy with depression rating scales.</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD011286-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>We used a comprehensive search strategy to identify all relevant studies regardless of language or publication status. </p> <p>The literature search was last updated in February 2016.</p> <section id="CD011286-sec-0051"> <h4 class="title">Electronic searches</h4> <p>1. <b>The Cochrane Common Mental Disorders Group's Specialised Register (CCMDCTR)</b> </p> <p>The Cochrane Common Mental Disorders Group maintains a specialised register of randomized controlled trials, the CCMDCTR. This register contains over 40,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating disorders, self‐harm and other mental disorders within the scope of this Group. The CCMDCTR is a partially studies based register with &gt;50% of reference records tagged to c12,500 individually PICO coded study records. Reports of trials for inclusion in the register are collated from (weekly) generic searches of Medline (1950‐), Embase (1974‐) and PsycINFO (1967‐), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also sourced from international trial registries, drug companies, the hand‐searching of key journals, conference proceedings and other (non‐Cochrane) systematic reviews and meta‐analyses. Details of <a href="http://cmd.cochrane.org/search-strategies-identification-studies" target="_blank">CCMD's core search strategies</a> (used to identify RCTs) can be found on the Group's website with an example of the core Medline search displayed in <a href="./appendices#CD011286-sec-0190">Appendix 1</a>. </p> <p>We searched the CCMDCTR (Studies and Reference Registers) to 5 February 2016 using the following free‐text terms: (*adenosyl* or SAM‐e or Samyr) </p> <p>2. <b>Biomedical databases</b> <br/> The original search of MEDLINE, EMBASE and PsycINFO was conducted in May 2012 (<a href="./appendices#CD011286-sec-0191">Appendix 2</a>). As the CCMDCTR includes these databases, further searches to February 2016 were conducted on the CCMDCTR alone. </p> <p>3. <b>International trial registries</b> were searched in February 2016 via ClinicalTrials.gov and the WHO trials portal (ICTRP) for additional unpublished or ongoing studies. </p> <p>We did not apply any restrictions on date, language or publication status to the searches.</p> </section> <section id="CD011286-sec-0052"> <h4 class="title">Searching other resources</h4> <section id="CD011286-sec-0053"> <h5 class="title">Reference checking</h5> <p>We checked the reference lists of all identified RCTs, other relevant papers, and major English, German and Italian textbooks of affective disorders. We searched the reference lists of identified studies for additional RCTs and health economics studies. </p> </section> <section id="CD011286-sec-0054"> <h5 class="title">Handsearching</h5> <p>We handsearched the annual conference proceedings of the American Psychiatric Association, the British Association of Psychopharmacology, the Congress of the International College of Neuropsychopharmacology, the European College of Neuropsychopharmacology and the National Congress of the Italian Psychiatric Association to June 2014. </p> </section> <section id="CD011286-sec-0055"> <h5 class="title">Personal communications</h5> <p>We identified the authors of significant papers since 2011 from authorship lists. We contacted them and other experts in the field and asked if they had knowledge of other studies, published or unpublished, relevant to the review. We requested pharmaceutical companies marketing SAMe products to provide relevant published and unpublished data.  </p> </section> </section> </section> <section id="CD011286-sec-0056"> <h3 class="title" id="CD011286-sec-0056">Data collection and analysis</h3> <section id="CD011286-sec-0057"> <h4 class="title">Selection of studies</h4> <p>Two authors (IG and LO) screened the results of the search using an over‐inclusive approach to construct a list of all papers that were potentially relevant. The two authors independently screened the abstracts for inclusion. We obtained the full‐texts of papers whenever there was any doubt about the relevance of an article or where the abstract and title looked relevant. Two authors (IG and LO) independently reviewed all the full‐text papers. We applied the full inclusion criteria to generate a list of studies to be considered for inclusion. </p> <p>Two authors (IG and LO) independently reviewed the list of studies to see whether they met the previously defined inclusion criteria. We planned to resolve disagreements by consensus or discussions with a third member of the review team (AY) and report this in the final review. We did not calculate a kappa statistic for measuring the agreement between the two authors as the authors agreed. We documented the selection process was documented through the completion of a PRISMA flow chart (<a href="#CD011286-fig-0001">Figure 1</a>). We described excluded studies in the <a href="./references#CD011286-sec-0198" title="">Characteristics of excluded studies</a> table. We listed multiple publications of the same study.  </p> <div class="figure" id="CD011286-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD011286-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD011286-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>For trials that met the inclusion criteria of the review, two review authors (IG and LO) independently extracted data concerning participant characteristics, intervention details and outcome measures using a previously piloted data collection form. We planned to solve any disagreements by consensus or discussions with a third member of the review team (AY). However, a kappa statistic for measuring the agreement between the two authors was not calculated as the authors agreed. </p> <p>We extracted data on the following comparisons:</p> <p> <ol id="CD011286-list-0005"> <li> <p>SAMe versus placebo as monotherapy;</p> </li> <li> <p>SAMe versus a TCA as monotherapy;</p> </li> <li> <p>SAMe versus SSRI as monotherapy;</p> </li> <li> <p>SAMe versus placebo as adjunctive treatment.</p> </li> </ol> </p> <p>We also planned to extract data on the comparison SAMe versus an active antidepressant agent as an adjunctive treatment; however, we found no studies. </p> <p>We planned to develop a data collection form for use with health economic studies, based on the template used to produce UK National Health Service Economic Evaluation Database (NHS EED) structured abstracts (<a href="./references#CD011286-bbs2-0063" title="CraigD , RiceS . NHS Economic Evaluation Database Handbook. York, UK: Centre for Reviews and Dissemination, University of York, 2007. ">Craig 2007</a>). </p> </section> <section id="CD011286-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KM and AY) independently assessed the risk of bias using the tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). This tool gives special consideration to the generation of randomisation sequences, allocation concealment, blinding procedures, the completeness of final data sets and selective reporting. We planned to solve any disagreements by consensus or discussion with a third member of the review team (GM). A kappa statistic for measuring the agreement between the two authors was not calculated as the authors agreed. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted the trial authors for clarification. For studies considered to be at high risk of bias due to the method of sequence generation, the inadequate concealment of sequence allocation, the absence of double blinding or for any other reason, we identified the key mechanism of bias. Where this mechanism was likely to influence a particular outcome measure, we investigated the effect of including the study in the relevant meta‐analysis using a sensitivity analysis. Sensitivity analyses were also conducted on studies where the risk of bias remained unclear, despite contact with the study authors. We recorded the source of information for each risk of bias judgement, including judgements based on unpublished information. </p> <p>For included health economic studies, we planned to assess the risk of bias and methodological quality using the Cochrane tool for assessing risk of bias (<a href="./references#CD011286-bbs2-0085" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. [DOI: http://dx.doi.org/10.1136/bmj.d5928] ">Higgins 2011b</a>), and the BMJ Checklist (<a href="./references#CD011286-bbs2-0072" title="DrummondMF , JeffersonTO . Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ1996;313:275‐83. ">Drummond 1996</a>). </p> <p>We used the five GRADE considerations to assess the body of evidence for each outcome (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We justified and documented all such assessments.  </p> </section> <section id="CD011286-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011286-sec-0061"> <h5 class="title">Continuous data</h5> <p>For continuously distributed outcomes, we calculated the mean difference (MD) between the groups. Where measures were reported using different scales, we used the standardised mean difference (SMD), if this was clinically appropriate. We also reported 95% confidence intervals (CI). </p> <p>Data would be checked for skew by calculation of the observed mean minus the lowest possible value minus (and by calculating the highest possible value minus the observed mean) and dividing this by the standard deviation. A ratio less than 2 suggests skew (<a href="./references#CD011286-bbs2-0043" title="AltmanDG , BlandJM . Statistics notes: presentation of numerical data. BMJ1996;312:572. ">Altman 1996a</a>; <a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). If the ratio is less than 1, there is strong evidence of a skewed distribution. When this was the case, we planned to exclude data from the analysis (<a href="./references#CD011286-bbs2-0043" title="AltmanDG , BlandJM . Statistics notes: presentation of numerical data. BMJ1996;312:572. ">Altman 1996a</a>). In studies in which the ratio was between 1 and 2, suggesting less marked skew, we planned to subject data to a sensitivity analysis. Studies with more than 200 participants were exempt from these processes as skewed data were less problematic in large studies.  </p> </section> <section id="CD011286-sec-0062"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous outcomes, we calculated the risk ratio (RR) of reported response, with 95% CI. We preferred the RR measure as the odds ratio is more difficult to interpret (<a href="./references#CD011286-bbs2-0108" title="SackettDL , DeeksJJ , AltmanDG . Down with odds ratios!. Evidence Based Medicine1996;1:164‐6. ">Sackett 1996</a>; <a href="./references#CD011286-bbs2-0112" title="SinclairJC , BrackenMB . Clinically useful measures of effect in binary analyses of randomized trials. Journal of Clinical Epidemiology1994;47:881‐9. ">Sinclair 1994</a>). </p> </section> </section> <section id="CD011286-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011286-sec-0064"> <h5 class="title">Cluster‐randomised trials</h5> <p>Cluster‐randomised studies are at risk of a 'unit of analysis' error (<a href="./references#CD011286-bbs2-0071" title="DivineGW , BrownJT , FrazerLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7:623‐9. ">Divine 1992</a>) and Type I errors (<a href="./references#CD011286-bbs2-0054" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>). Where clustering was suspected, we contacted the authors with a request that they supplied intra‐class correlation coefficients of their clustered data and adjust for this using methods described by <a href="./references#CD011286-bbs2-0079" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>. If clustering was incorporated, we planned to present the data in the form of a parallel‐group randomised study, with adjustments for clustering effects. If cluster studies were appropriately analysed, we planned to conduct synthesis with other studies using the generic inverse variance technique. </p> </section> <section id="CD011286-sec-0065"> <h5 class="title">Cross‐over trials</h5> <p>For cross‐over studies, we considered only results from the first randomised portion. Data from the second phase of such studies are potentially subject to the confounding influences of discontinuation effects and persistent treatment effects. </p> </section> <section id="CD011286-sec-0066"> <h5 class="title">Studies with multiple treatment groups</h5> <p>When a study had more than two intervention arms, we included only those intervention and control arms meeting the inclusion criteria of the review. We entered all relevant intervention groups of a multi‐intervention study in the <a href="./references#CD011286-sec-0197" title="">Characteristics of included studies</a> table and assessed these studies for any risk of bias. In particular, we sought reporting biases, such as the combining of groups on different doses of medication or the presentation of different outcomes in the comparison of different groups. Where appropriate, we combined data from all relevant experimental intervention groups of the study into a single group, and combined data from all relevant control intervention groups into a single control group (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> </section> <section id="CD011286-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We analysed all data on an intention‐to‐treat (ITT) basis. If it was not clear why data were missing, we contacted trialists to either provide the data or to explain why it was missing. However, we were unable to obtain any additional data. Careful consideration was given to the reason why data were missing, and whether the data were missing at random or their absence was in some way related to the outcome measure. We documented this where possible.    </p> <p>We considered the impact of missing data separately for different key outcomes. Where participants had withdrawn from the trial before reaching the end of the study period, we planned to assume that their condition would have remained unaltered had they continued to the end, that we would use the last observation carried forward (LOCF). However, it must be noted that ITT and LOCF methods have some limitations and can lead to bias as the means are likely to be distorted (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). In the event, we were unable to use the LOCF method as, in all cases, individual raw participant data were not available. We addressed the missing data as follows: </p> <p> <ol id="CD011286-list-0006"> <li> <p>For continuous efficacy outcomes, we imputed missing data using the conservative approach of assuming that these participants had no change in their mean score on the HAM‐D from baseline to the endpoint. As we did not have access to the raw participant baseline scores, we used the mean baseline score of all participants. To assess the robustness of the assumptions, we carried out sensitivity analyses where the participants were assumed to have had the same mean change as the other participants. </p> </li> <li> <p>For dichotomous outcomes, we imputed missing data based on the consideration of a 'worst‐case' scenario. To assess the robustness of the assumption, we carried out sensitivity analyses based on a 'best‐case' scenario. </p> </li> </ol> </p> <p>Variation in the degree of missing data was considered as a source of heterogeneity. We investigated the impact of these assumptions by undertaking a sensitivity analysis (<a href="./references#CD011286-bbs2-0041" title="AldersonP , GreenS , HigginsJPT . Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. 4.2.2. Chichester, UK: Wiley &amp; Sons, Ltd, 2004. ">Alderson 2004</a>). Where standard error data were presented, we calculated standard deviations from the standard error (<a href="./references#CD011286-bbs2-0044" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996b</a>). In the absence of any such data, we imputed standard deviations (<a href="./references#CD011286-bbs2-0076" title="FurukawaTA , BarbuiC , CiprianiA , BrambillacP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59:7‐10. ">Furukawa 2006</a>), and undertook sensitivity analyses to assess the validity of this process.  </p> <p>For a detailed description of the procedures see <a href="./appendices#CD011286-sec-0192">Appendix 3</a> (Dealing with missing data). </p> </section> <section id="CD011286-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the I<sup>2</sup> statistic. We used a P value of 0.10 as an indication of significant heterogeneity in meta‐analyses of small studies, as the Chi<sup>2</sup> test may be underpowered to detect heterogeneity in these circumstances. According to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, the bands of interpretation for I<sup>2</sup> are as follows: 0% to 40%: may be unimportant; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity and 75% to 100%: may have considerable heterogeneity (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We took values above 30% to indicate moderate heterogeneity (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>), and sought sources of heterogeneity. We considered studies with heterogeneity greater than 75% too heterogeneous to combine in a meta‐analysis. Where we detected moderate or greater heterogeneity, we sought possible causes including the diagnosis, the demographic profile of the participants, the dose of agents used and the duration of treatment. We also considered variation in the degree of missing data as a source of heterogeneity. </p> </section> <section id="CD011286-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>Where there were more than 10 studies contributing to an outcome, we planned to construct funnel plots to examine the data for small‐study effects (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). In addition to publication bias, such effects may have been due to selective reporting, poor methodological quality leading to spuriously inflated effects in smaller studies, true heterogeneity of effect, artefact and chance (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We considered selective outcome reporting as part of the quality assessment procedure and reported any instances. </p> </section> <section id="CD011286-sec-0070"> <h4 class="title">Data synthesis</h4> <p>Data from trials were combined in the meta‐analyses only if this was appropriate, that was the participants, interventions, comparisons and outcomes were sufficiently similar. The assessment of heterogeneity acted as a test of these judgements. We used a random‐effects model as it assumes that studies estimate different but related effects (<a href="./references#CD011286-bbs2-0068" title="DerSimonianR , LairdN . Meta‐analysis in Clinical Trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). We considered a random‐effects model appropriate because changes in the depression rating scales may measure similar but different effects. For instance, a change in total score may reflect improvements in physical symptoms of depression (e.g. sleep disturbance, appetite, lassitude), while in another study it may reflect a change in psychological symptoms such as feelings of guilt or hopelessness. Two authors (IG and LO) entered data into the Review Manager 5 (<a href="./references#CD011286-bbs2-0106" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD011286-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>As discussed in the introduction, participants with certain subtypes of depression may respond differently to SAMe and to other treatments. We planned to undertake the following subgroup analyses, to examine the contribution of potential effect modifiers to heterogeneity. </p> <p> <ol id="CD011286-list-0007"> <li> <p>Data from parenteral and oral administration of SAMe: different methods of administration may affect efficacy and the placebo response. </p> </li> <li> <p>Depression with and without psychotic features: psychotic features are associated with more severe episodes of depression and they may respond differently to mild‐moderate depression or to non‐psychotic episodes of similar severity. </p> </li> <li> <p>Treatment‐resistant depression: participants with this category of depression, by definition, will have failed to respond to at least two adequate trials of antidepressants and may respond differently to trial medications. </p> </li> <li> <p>Atypical depression: participants with this category of depression characteristically respond optimally to MAOIs and may respond differently to trial medications. </p> </li> <li> <p>Anxiety: anxiety detrimentally affects treatment outcome.</p> </li> </ol> </p> <p>It is recognised that any findings from these analyses are hypothesis‐forming.</p> </section> <section id="CD011286-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses.</p> <p> <ol id="CD011286-list-0008"> <li> <p>Studies where methodological factors may be sources of bias and likely to impact on the particular outcome under investigation. For instance, studies with inadequate blinding procedures may be liable to bias because of the effects of participants' and observers' expectations regarding their allocated treatment. </p> </li> <li> <p>Studies with high levels of missing data (i.e. more than 30%). In studies with high drop‐out rates, the assumptions involved in the use of the LOCF approach may introduce considerable bias. </p> </li> <li> <p>Studies using cluster randomisation. This method introduces the risk of bias in several ways. These include the possibility of recruitment bias, baseline imbalance and incorrect analysis (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). There is also the question of how comparable these studies are with individually randomised trials. The influence of these potential sources of bias on the outcome measures identified in a review are difficult to predict. However, as there is a possibility of bias, we planned to investigate it routinely. </p> </li> </ol> </p> <p>It is recognised that any findings from these analyses are hypothesis‐forming.</p> <section id="CD011286-sec-0073"> <h5 class="title">Economics issues</h5> <p>We planned to summarised characteristics and results of included economic evaluations using additional tables, supplemented by a narrative summary that would compare and evaluate methods used and principal results between studies. </p> <p>In addition, we planned to tabulate unit cost data, when available.</p> </section> <section id="CD011286-sec-0074"> <h5 class="title">'Summary of findings' tables</h5> <p>We constructed a 'Summary of findings' table according to the recommendations of the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> for each of the comparisons (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). For each comparison, the table described the form of intervention, details of scales and time frames, the number of participants and studies for each outcome, a measure of the typical burden of non‐response to treatment (i.e. the assumed risks for non‐response, summary of the intervention effect: indices of absolute and relative magnitudes) and the quality of the body of evidence for each outcome. </p> <p>Included outcomes were:</p> <p> <ol id="CD011286-list-0009"> <li> <p>change in the mean score in the specified depression rating scores from baseline to end of treatment; </p> </li> <li> <p>proportions of participants responding to treatment;</p> </li> <li> <p>proportions of participants achieving remission;</p> </li> <li> <p>participants dropping out of treatment during the study period for any reason;</p> </li> <li> <p>participants experiencing troublesome adverse effects of any nature.</p> </li> </ol> </p> <section id="CD011286-sec-0075"> <h6 class="title">Notes on the 'Summary of findings' table</h6> <p>The 'Summary of findings' table presented the main group comparisons only.</p> <p>For dichotomous outcomes, the table provided both a relative measure (the RR) of non‐response and the absolute risk reduction (ARR). For continuous data, the table presented the MD or SMD. </p> <p>We presented typical assumed risks for non‐response in the control group and cited the sources of this information. Participants in the included studies were experiencing depression, and so the baseline assumed risk of non‐response for a median control group seemed the most helpful information to present. We cited the information on which this information was based. We calculated a corresponding intervention risk from the RR and the assumed control risk. </p> <p>We used the GRADE approach to assessing the quality of the body of evidence. We adhered to the standard methods for the preparation and presentation of results outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011286-bbs2-0084" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011286-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011286-sec-0076"></div> <section id="CD011286-sec-0077"> <h3 class="title">Description of studies</h3> <section id="CD011286-sec-0078"> <h4 class="title">Results of the search</h4> <p>We identified 650 references: 82 through CCMDCTR, 528 through other electronic databases and 40 through additional resources. After we excluded 221 duplicates, we read the abstracts and excluded a further 362 references. We considered 67 references relevant for our review and tried to retrieve full‐text copies to assess their eligibility. Some studies that were possibly eligible reported heterogeneous groups of participants without the possibility to separate out data from those participants with 'unipolar' depression (<a href="./references#CD011286-bbs2-0012" title="AlvarezE , UdinaC , GuillamatR . Double blind study on the antidepressant activity of sulfoadenosyl‐L‐methionine (SAMe): clinical and biological factors [Estudio doble ciego sobre la efectividad antidepresiva del SAMe; factores clínicos y biológicos]. Revista del Departamento de Psiquiatría de la Facultad de Medicina de Barcelona1984;11(4):275‐88. ">Alvarez 1984</a>; <a href="./references#CD011286-bbs2-0021" title="DeLeoD . S‐adenosylmethionine as an antidepressant: a double‐blind trial versus placebo. Current Therapeutic Research, Clinical and Experimental1987;41(6):865‐70. ">De Leo 1987</a>; <a href="./references#CD011286-bbs2-0022" title="Delle ChiaieR , BoissardG . Meta‐analysis of two European multicenter controlled trials with ademetionine (SAMe) in major depression. 6th World Congress of Biological Psychiatry; 1997 22‐27 Jun; Nice, France. 1997. Delle ChiaieR , PancheriP . Combined analysis of two controlled, multicentric, double‐blind studies to assess efficacy and safety of sulfo‐adenosyl‐methionine (SAMe) vs. placebo (MC1) and SAMe vs. clomipramine (MC2) in the treatment of major depression [Analisi combinata di due studi controllati, multicentrici, in doppio cieco per la valutazione di efficacia e tollerabilita' di SAMe vs. placebo (MC1) e di SAMe vs. clomipramina (MC2) nel trattamento della depressione maggiore]. Giornale Italiano di Psicopatologia1999;5:1‐16. ">Delle Chiaie 1999</a>; <a href="./references#CD011286-bbs2-0026" title="JanicakPG , LipinskiJ , DavisJM , AltmanE , SharmaRP . Parenteral S‐adenosylmethionine (SAMe) in depression; literature review and preliminary data. Psychopharmacology Bulletin1989;25(2):238‐42. JanicakPG , LipinskiJ , DavisJM , ComatyJE , WaternauxC , CohenB , et al. S‐adenosylmethionine in depression. A literature review and preliminary report. Alabama Journal of Medical Sciences1988;25(3):306‐13. ">Janicak 1988</a>; <a href="./references#CD011286-bbs2-0027" title="KufferleB , GrunbergerJ . Early clinical double‐blind study with S‐adenosyl‐L‐methionine: a new potential antidepressant. Advances in Biochemical Psychopharmacology1982;32:175‐80. ">Kufferle 1982</a>; <a href="./references#CD011286-bbs2-0032" title="SalmaggiP , BressaGM , NicchiaG , ConiglioM , LaGrecaP , LeGrazieC . Double‐blind, placebo‐controlled study of S‐adenosyl‐L‐methionine in depressed postmenopausal women. Psychotherapy and Psychosomatics1993;59(1):34‐40. SalmaggiP , BressaGM , NicciaG , ConiglioM , LaGrecaP , LeGrazieC . Oral S‐adenosylmethionine (SAMe) in the treatment of menopausal depressive disorder (MDD): a double‐blind placebo controlled trial. European Journal of Clinical Investigation1991;21(2 pt 2):58. ">Salmaggi 1991</a>). We approached the authors in order to obtain original unpublished data but unsuccessfully and we excluded them. We also contacted Prof M. Fava to achieve clarification on randomisation in his study (<a href="./references#CD011286-bbs2-0025" title="FavaM , RosenbaumJF , BirnbaumR , KellyK , OttoMW , MacLaughlinR . The thyrotropin response to thyrotropin‐releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatrica Scandinavica1992;86(1):42‐5. ">Fava 1992</a>); his answer did not permit us to include the study in our review. Finally, eight studies met inclusion criteria for our review and we included them in the qualitative and quantitative analysis. We categorised three studies as ongoing, nine references and one study awaiting classification and excluded the remaining studies for various reasons (see <a href="#CD011286-fig-0001">Figure 1</a> for PRISMA flow diagram). </p> <p>We identified no RCTs providing economic analyses.</p> </section> <section id="CD011286-sec-0079"> <h4 class="title">Included studies</h4> <p>This systematic review included eight studies with 934 participants. Although we contacted the authors of the included studies and received a response in some cases, attempts to obtain additional unpublished data and information regarding missing data were almost always unsuccessful. </p> <p>See <a href="./references#CD011286-sec-0197" title="">Characteristics of included studies</a> table. </p> <section id="CD011286-sec-0080"> <h5 class="title">Study design</h5> <p>All the included studies were RCTs and were reported to be double blind. Two studies were multicentre (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>). One study was three‐armed with SAMe, an alternative pharmacological treatment and placebo (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). Two studies were two‐armed with SAMe versus placebo as monotherapy (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>) or as adjunctive therapy (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). The remaining five studies were two‐armed with SAMe versus an alternative pharmacological treatment (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). The <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> study included a cross‐over phase in its design, though the report included in our review was focused on the data for the first phase of treatment. </p> <p>There were no trials comparing SAMe with an active antidepressant as an adjunctive therapy. </p> </section> <section id="CD011286-sec-0081"> <h5 class="title">Sample size</h5> <p>Overall, the review included 934 participants. Five studies recruited fewer than 100 participants (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>), and only three studies recruited more than 200 participants overall (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). </p> <p>The mean sample size per arm was 55 participants (range 11 to 148).</p> </section> <section id="CD011286-sec-0082"> <h5 class="title">Participants</h5> <p>Two studies enrolled only inpatients (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>), four studies only outpatients (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). One study enrolled both inpatients and outpatients (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>), and for the remaining trial the setting was unclear (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). All studies enrolled people with a diagnosis of major depression, according to DSM‐III (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>), DSM‐III‐R (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>), or DSM‐IV (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). All but one study (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>, only men) recruited both women and men. Three studies provided participants over the age range of our review, including people aged 18 to 80 years (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). Our protocol restricted the age range to 18 to 70 years (<a href="./references#CD011286-bbs2-0119" title="GaliziaI , OldaniL , MacritchieK , AmariE , DougallD , JonesTN , et al. S‐adenosyl methionine (SAM‐e) for depression in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011286] ">Galizia 2014</a>). We decided to include these studies after consideration of the mean age of the participants. </p> <p><a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> reported a past episode of mania in one participant in the comparison group. As per protocol, we should have excluded participants with bipolar depression. We decided to include this study because it was only one participant and nothing in the text showed that he reported different response to treatment or had a manic switch during the trial. </p> <p>Only one study examined a particular subgroup of participants with major depression, namely SSRI non‐responders (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). We analysed this subgroup separately. Two studies excluded participants with history of resistance to TCA treatment (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). </p> <p>Six studied excluded people who had psychotic symptoms (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> </section> <section id="CD011286-sec-0083"> <h5 class="title">Intervention/comparisons</h5> <p>Studies used SAMe as monotherapy (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>) or as an adjunctive therapy (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). Specifically, SAMe was adjunct to SSRIs (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> <p>The mean duration of treatment was 5.3 weeks (range 2 to 12 weeks).</p> <p>The administration of SAMe was oral at a target dose of 1600 mg/day (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>) or parenteral at a dose of 200 mg/day to 400 mg/day (intravenous <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>, intramuscularly <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>). According to our protocol, we undertook a subgroup analysis to examine data from parenteral and oral administration of SAMe (<a href="./references#CD011286-bbs2-0119" title="GaliziaI , OldaniL , MacritchieK , AmariE , DougallD , JonesTN , et al. S‐adenosyl methionine (SAM‐e) for depression in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011286] ">Galizia 2014</a>). In one study, for participants who complained of adverse effects the drug, dose could be reduced from the third week on, down to a minimal dose of imipramine of 100 mg/day and SAMe of 1200 mg/day; the study excluded participants who tolerated this dose poorly from the study (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>). The <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a> trial withdrew participants who were unable to tolerate the study medications, per protocol. One study allowed a dose increase to 3200 mg/day for non‐responders (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>); they allowed participants who experienced intolerable adverse effects at the higher dose to decrease the dose to the previous level. Four studies specified the exact formulation of the SAMe used in the trial: 1,4‐butanedisulphonate‐SAMe (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>), and SAMe tosylate (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> <p>Two studies compared SAMe with placebo (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>), four studies SAMe with imipramine (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>), and one study SAMe with desipramine (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). Three cases titrated imipramine up to 150 mg/day (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>), while in the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> trial, participants received a dose of 140 mg/day; desipramine was titrated up to 250 mg/day. One study was three‐armed comparing SAMe with escitalopram 10‐20 mg/day and placebo (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). </p> <p>Some studies allowed the use of benzodiazepine as a hypnotic (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). However, none of the studies analysed whether the use of benzodiazepines could have somehow affected the outcomes. </p> </section> <section id="CD011286-sec-0084"> <h5 class="title">Outcomes</h5> <p>We categorised all outcomes in this review as short‐term, as the maximum endpoint of the included studies was 12 weeks. </p> <section id="CD011286-sec-0085"> <h6 class="title">Primary outcomes</h6> <p>All included studies evaluated the efficacy of treatment by administration of the Hamilton Depression Scale (HAM‐D). However, they used different versions of this rating scale: 31‐item HAM‐D in <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; and <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; 17‐item HAM‐D in <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; and <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>; 21‐item HAM‐D in <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; and <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>. In our analysis, we applied the SMD in order to measure the treatment efficacy. </p> <p>The efficacy assessments also included the Beck Depression Inventory in two studies (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>), and the 14‐item Hamilton Rating Scale for Anxiety and 20‐item Zung's Self‐Rating Scale for Depression in one study (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). Two studies evaluated the MADRS (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>). Other scales included the Clinical Global Impression scale (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>), the Clinical Global Impression ‐ Severity (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>), Clinical Global Impression ‐ Improvement versions (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). Further, secondary measures of efficacy included the Inventory of Depressive Symptomatology ‐ Clinician Rating and the Inventory of Depressive Symptomatology ‐ Self Report in the <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> study, the Carroll Rating Scale for Depression in the <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> study. </p> <p>According to the hierarchy of outcome measures of this review, we prioritised the data from the HAM‐D. </p> <p>In one study, the primary outcome was the correlation between plasma SAMe levels and the degree of clinical improvement; blood samples for the analysis of plasma SAMe levels were collected (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). </p> <p>In the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> trial, we extrapolated data regarding the efficacy of the treatment from the figure reported in the paper, as no other information was available. To check the accuracy of our calculations, we verified if the extrapolated MDs matched with the per cent improvement in the mean scores shown in the paper. We conducted a sensitivity analysis to assess the robustness of this assumption. </p> <p>We could extract data for the analysis of the outcome "Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale" in all but one study (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). </p> <p>The 'Risk of bias' table of the <a href="./references#CD011286-sec-0197" title="">Characteristics of included studies</a> table states the drop‐out rates of individual trials, the distribution of drop‐outs among trials arms and the reasons for drop‐out. </p> <p>We could extract data for the analysis of the acceptability outcomes related to the drop‐outs in all but two studies (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>). However, the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study did not provide data for the quantitative evaluation of the drop‐outs reasons. </p> </section> <section id="CD011286-sec-0086"> <h6 class="title">Secondary outcomes</h6> <p>Response to treatment was defined as a reduction of more than 50% on HAM‐D (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>) or at least 50% (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). Treatment‐responders were also defined those participants who had a Clinical Global Impression score of 2 or less at the end of the study (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>) or a Clinical Global Impression ‐ Improvement score of less than 3 at endpoint (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> <p>All but one study (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>) provided data for the analysis of the outcome "Efficacy. Response to treatment". </p> <p>Remission was determined as a final HAM‐D score of less than 7 (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>) or 7 or less (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). In addition, <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a> considered remission as a Clinical Global Impression ‐ Severity score of 1 at endpoint. Only data from these two studies could be extracted to evaluate the remission rates. </p> <p>All studies evaluated the tolerability and safety of the treatment by reporting adverse effects. Some studies applied instruments, such as the Somatic Symptom Checklist (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>), Systematic Assessment for Treatment Emergent Events (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>), and the Systematic Assessment for Treatment of Emergent Events‐Specific Inquiry (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). Almost all studies performed laboratory tests, electrocardiogram (ECG) and assessment of vital signs. </p> <p>Three studies provided the rates of adverse effects of any nature experienced by participants (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). </p> <p>Most studies did not provide enough detailed data regarding specific adverse effects to carry out complete quantitative analyses. </p> </section> </section> </section> <section id="CD011286-sec-0087"> <h4 class="title">Excluded studies</h4> <p>Twenty‐eight studies initially considered for potential inclusion in the review and retrieved as full‐articles did not meet our inclusion criteria and were excluded for different reasons, as follows: inappropriate diagnosis, presence of comorbidity, inappropriate outcomes, inappropriate intervention, inappropriate comparator, unsuitable study design, methodological issues and heterogeneous group of participants. </p> <p>See the <a href="./references#CD011286-sec-0198" title="">Characteristics of excluded studies</a> table for details of the respective reasons for excluding each study. </p> <section id="CD011286-sec-0088"> <h5 class="title">Studies awaiting classification</h5> <p>We identified nine additional references by screening reference lists; it is unclear as to whether these are reports of RCTs already included (e.g. <a href="./references#CD011286-bbs2-0051" title="BellKM , PotkinSG , CarreonL , PlotL , BunneyW . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind, randomized comparison with desipramine. American Journal Psychiatry (submitted). ">Bell (personal communication)</a><b>)</b> or otherwise. As we could identify no abstract or full‐text reference to ascertain study characteristics, we have currently listed these as additional references (see <a href="./references#CD011286-bbs2-0045" title="AlvarezE , UdinaC , GuillamatR . Shortening of latency period in depressed patients treated with SAMe and other antidepressant drugs. Cell Biology Reviews1987;S1:103‐10. ">Alvarez 1987</a>; <a href="./references#CD011286-bbs2-0051" title="BellKM , PotkinSG , CarreonL , PlotL , BunneyW . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind, randomized comparison with desipramine. American Journal Psychiatry (submitted). ">Bell (personal communication)</a>; <a href="./references#CD011286-bbs2-0052" title="BellK , PlonL , NabelM . A controlled clinical trial of S‐adenosylmethionine treatment of depression. Annual Review of Cell and Developmental Biology1987;S1:111‐20. ">Bell 1987</a>; <a href="./references#CD011286-bbs2-0069" title="DiPadovaC , GiudiciA , BoissardG . Ademetionine and depression. IV Workshop on methionine metabolism: molecular mechanisms and clinical implications; 2000 Feb 20‐24; Granada, Spain. 2000:295‐9. ">Di Padova 2000</a>: <a href="./references#CD011286-bbs2-0074" title="FazioC , AndreoliV , AgnoliA , CasacchiaM , CerboR . Therapy of schizophrenic and depressive disorders with S‐adenosylmethionine. Clinical Pharmacology &amp; Therapeutics1974;2:1015. ">Fazio 1974</a>; <a href="./references#CD011286-bbs2-0090" title="MacherJR . A double‐blind, placebo‐controlled trial of intravenous ademetionine (SAMe) in the treatment of major depression (DSM III‐R). International Clinical Psychopharmacology (in press). ">Macher (in press)</a>; <a href="./references#CD011286-bbs2-0091" title="MacherJP . A double blind placebo controlled trial of intravenous ademetionine (SAMe) in the treatment of major depression. Progress in Neuro‐Psychopharmacology &amp; Biological Psychiatry2000;24(2):207‐25. ">Macher 2000</a>; <a href="./references#CD011286-bbs2-0100" title="PancheriP , RacagniG , Delle ChiaieRD . Recent experimental and clinical findings of the efficacy and safety of adementionine (SAMe) in the pharmacological treatment of depression. Giornale Italiano di Psicopatologia1997;3:1‐23. ">Pancheri 1997</a>; <a href="./references#CD011286-bbs2-0103" title="PinzelloA , AndreoliV . SAMe‐dependent transmethylation in the depressive syndromes: evaluation of the therapeutic effect of S‐adenosylmethionine using Hamilton Rating Scale [Le transmetilazioni SAM‐dipendenti nelle sindromi depressive. Valutazione dell'effetto terapeutico della S‐adenosilmetionina con la scala di Hamilton]. Quaderno Terapeutico Sperimentale; Supplemento Biochimica e Biol Sperimentale1972;10(2):3‐11. ">Pinzello 1972</a>). </p> <p>One additional study identified from the CCMDCTR search was a handsearch record submitted by the Iberoamerican Cochrane Centre in the 1980s (<a href="./references#CD011286-bbs2-0037" title="QuirosG . Assessment of a new drug for depression: S‐adenosyl‐L‐methionine [Valoracion de un nuevo farmaco en el tratamiento de las depresiones: la S‐Adenosyl‐L‐Metionina]. Psicopatologia1982;2(3):265‐74. ">Quiros 1982</a>, CENTRAL ID: CN‐00711163). </p> <p>For further details of these studies see <a href="./references#CD011286-sec-0199" title="">Characteristics of studies awaiting classification</a> table. </p> </section> <section id="CD011286-sec-0089"> <h5 class="title">Ongoing studies</h5> <p>We identified three ongoing studies, all described as double‐blind, randomised, placebo‐controlled trials involving adults with a diagnosis of major depressive disorder. Two studies were three‐armed with SAMe plus cofactors folinic acid and vitamin B12, enhanced SAMe combination nutraceutical formulation and placebo (<a href="./references#CD011286-bbs2-0038" title="SarrisJ . Nutraceuticals as monotherapy treatments in major depressive disorder: a double‐blind, randomised, placebo‐controlled trial, 2013. www.anzctr.org.au/ACTRN12613001299796.aspx (accessed 3 August 2016). [www.anzctr.org.au/ACTRN12613001299796.aspx] SarrisJ , MurphyJ . The efficacy of S‐adenosyl methionine (SAMe) and a combination nutraceutical as monotherapy treatments in major depressive disorder: a double‐blind, randomised, placebo‐controlled trial. www.anzctr.org.au/ACTRN12613001299796.aspx (accessed 3 August 2016). ">ACTRN12613001299796</a>; <a href="./references#CD011286-bbs2-0039" title="SarrisJ . The efficacy of S‐adenosylmethionine (SAMe) and a combination nutraceutical as adjunctive treatments in depression: a double‐blind, randomized, placebo‐controlled trial, 2013. www.anzctr.org.au/ACTRN12613001300763.aspx (accessed 3 August 2016). [www.anzctr.org.au/ACTRN12613001300763.aspx] ">ACTRN12613001300763</a>), while the other study compared adjunctive SAMe as adjunctive therapy versus adjunctive placebo (<a href="./references#CD011286-bbs2-0040" title="MSI Methylation Sciences, Inc . A double‐blind, placebo‐controlled, randomized add‐on study of MSI‐195 (Methylation Sciences Inc. S‐adenosyl‐L‐methionine, SAMe) for patients with major depressive disorder (MDD) who have had an inadequate response to current antidepressant therapy, 2013. clinicaltrials.gov/show/NCT01912196 (accessed 3 August 2016). [clinicaltrials.gov/show/NCT01912196] ">NCT01912196</a>). </p> </section> </section> </section> <section id="CD011286-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>Detailed assessment of risk of bias across all studies is presented in the <a href="./references#CD011286-sec-0197" title="">Characteristics of included studies</a> table and <a href="#CD011286-fig-0002">Figure 2</a> and <a href="#CD011286-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011286-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011286-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011286-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011286-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011286-sec-0091"> <h4 class="title">Allocation</h4> <section id="CD011286-sec-0092"> <h5 class="title">Random sequence generation</h5> <p>Only two studies were at low risk of bias for random sequence generation, as the investigators sufficiently described the random component in the sequence generation process (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). The remaining studies were rated as having unclear risk of bias, since the methods of randomisation were not described in sufficient details. </p> </section> <section id="CD011286-sec-0093"> <h5 class="title">Allocation concealment</h5> <p>Three studies were at low risk of bias for allocation concealment, as the investigators used a conceal allocation methods that did not allow participants and investigators enrolling participants to foresee assignment (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). The remaining studies were rated as unclear as the methods of concealment were not described in sufficient detail. </p> </section> </section> <section id="CD011286-sec-0094"> <h4 class="title">Blinding</h4> <section id="CD011286-sec-0095"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>With regard to the risk of performance bias, four studies were at low risk of bias as they ensured blinding of participants and personnel, and it was unlikely that the blinding could have been broken (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> <p>The other studies were at unclear risk of performance bias, because the methods to secure the blinding were not fully described (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). In addition, the allocation concealment was unclear. </p> </section> <section id="CD011286-sec-0096"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>With regard to the risk of detection bias, four studies were at low risk of bias as they ensured blinding of outcome assessment, and it was unlikely that the blinding could have been broken (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> <p>The other studies were at unclear risk of detection bias, because the methods to secure the blinding were not fully described (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). In addition, the allocation concealment was unclear. </p> </section> </section> <section id="CD011286-sec-0097"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies were at low risk of attrition bias. In the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> and <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> trials, missing outcomes were too few to impact on the observed effect size. In both cases, the reason for drop‐outs were stated. In the <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a> study, an ITT analysis was available and all non‐completers were mentioned with reasons for drop‐out. </p> <p>One study was at high risk of attrition bias because they used only data on completers and did not state the reason for missing participants (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). </p> <p>The remaining four studies were at unclear risk of attrition bias. It was unclear whether <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> used an ITT analysis. Although <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a> and <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a> carried out an ITT analysis, they did not fully describe non‐completers. <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> had a very large proportion of drop‐outs (almost 50%). </p> </section> <section id="CD011286-sec-0098"> <h4 class="title">Selective reporting</h4> <p>Across all the studies, the risk of reporting bias was low. This was given careful consideration, as no study protocols were available. However, all expected outcomes, including those that were prespecified in the protocol section of the final reports, were included in the results. </p> </section> <section id="CD011286-sec-0099"> <h4 class="title">Other potential sources of bias</h4> <p>The risk of other bias was low as we identified no other potential sources of bias.</p> </section> </section> <section id="CD011286-sec-0100"> <h3 class="title" id="CD011286-sec-0100">Effects of interventions</h3> <p>See: <a href="./full#CD011286-tbl-0001"><b>Summary of findings for the main comparison</b> S‐adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults</a>; <a href="./full#CD011286-tbl-0002"><b>Summary of findings 2</b> S‐adenosyl methionine as monotherapy compared to tricyclic antidepressant agent as monotherapy for depression in adults</a>; <a href="./full#CD011286-tbl-0003"><b>Summary of findings 3</b> S‐adenosyl methionine as monotherapy compared to SSRI antidepressant agent as monotherapy for depression in adults</a>; <a href="./full#CD011286-tbl-0004"><b>Summary of findings 4</b> S‐adenosyl methionine as adjunctive treatment compared to placebo as add‐on to SSRI for depression in adults</a> </p> <p>We extracted data on the following comparisons:</p> <p> <ol id="CD011286-list-0010"> <li> <p>SAMe versus placebo as monotherapy;</p> </li> <li> <p>SAMe versus a TCA as monotherapy;</p> </li> <li> <p>SAMe versus SSRI as monotherapy;</p> </li> <li> <p>SAMe versus placebo as adjunctive treatment.</p> </li> </ol> </p> <p>Where published data were not sufficient to evaluate our outcomes, we contacted the authors in order to obtain unpublished data; however, we received no responses. </p> <section id="CD011286-sec-0101"> <h4 class="title">Comparison 1: S‐adenosyl methionine versus placebo as monotherapy</h4> <p>Two studies were eligible for this comparison (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). See <a href="./full#CD011286-tbl-0001">summary of findings Table for the main comparison</a>. The <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> study was at low risk of selection, performance, detection, attrition, reporting and other bias. The <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> study was at unclear risk of attrition bias and at low risk of bias in the other domains. </p> <section id="CD011286-sec-0102"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0103"> <h6 class="title">1.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>In this analysis, a reduction in depression rating scale score (indicated by a negative sign) represents an improvement. </p> <p>Overall, there was no strong evidence of a difference between SAMe and placebo as monotherapy in terms of efficacy in the treatment of depression, measured as change in the mean scores on depression rating scale (SMD ‐0.54, 95% CI ‐1.54 to 0.46; P = 0.29; 142 participants; 2 studies) (<a href="./references#CD011286-fig-0004" title="">Analysis 1.1</a>). The evidence contributing to this outcome was very low quality. </p> <p>The studies showed a high level of heterogeneity (I<sup>2</sup> = 72%; P = 0.06), which has been investigated in the <a href="#CD011286-sec-0176">Discussion</a>. </p> </section> <section id="CD011286-sec-0104"> <h6 class="title">1.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>There was no strong evidence of a difference between the two arms with regard to the level of drop‐outs (RR 0.88, 95% CI 0.61 to 1.29; P = 0.52; 142 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011286-fig-0005" title="">Analysis 1.2</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0105"> <h6 class="title">1.3 Acceptability. Participants dropping out of treatment during study period because of adverse effects </h6> <p>There was no strong evidence of a difference between SAMe and placebo as monotherapy in terms of drop‐outs due to adverse effects (RR 0.70, 95% CI 0.16 to 3.01; P = 0.64; 142 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011286-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD011286-sec-0106"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0107"> <h6 class="title">1.4 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>In this analysis, an increase of RR represents a positive outcome indicating response to treatment in the SAMe group. </p> <p>There was no evidence that SAMe was superior to placebo as monotherapy in terms of response to treatment (RR 1.77, 95% CI 0.51 to 6.13; P = 0.37; 142 participants; 2 studies) (<a href="./references#CD011286-fig-0007" title="">Analysis 1.4</a>). The evidence contributing to this outcome was low quality. </p> <p>The two studies included in this analysis showed a non‐significant heterogeneity (I<sup>2</sup> = 49%; P = 0.16). </p> </section> <section id="CD011286-sec-0108"> <h6 class="title">1.5 Efficacy. Remission, defined as a depression rating scale score within the normal range at end of study </h6> <p>In this analysis, an increase of RR represents a positive outcome indicating response to treatment in the SAMe group. </p> <p>Only the <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> study contributed to this outcome. There was no evidence of a difference between the two treatment arms with regard to remission (RR 1.69, 95% CI 0.85 to 3.36; P = 0.14; 124 participants; 1 study) (<a href="./references#CD011286-fig-0008" title="">Analysis 1.5</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0109"> <h6 class="title">1.6 Acceptability. Participants experiencing troublesome adverse effects of any nature</h6> <p>There were no available data to conduct this analysis.</p> </section> <section id="CD011286-sec-0110"> <h6 class="title">1.7 Acceptability. Participants experiencing specific adverse effects identified in protocol </h6> <p>One study detailed the adverse effects (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>). In the SAMe group, one participant experienced manic symptoms and headache (<a href="./references#CD011286-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD011286-fig-0010" title="">Analysis 1.7</a>); in the placebo group, two participants reported flatulence (<a href="./references#CD011286-fig-0011" title="">Analysis 1.8</a>). The conducted analyses showed no strong evidence of a difference between the two treatment arms (<a href="./references#CD011286-fig-0009" title="">Analysis 1.6</a>: RR 2.10, 95% CI 0.10 to 44.40; P = 0.63; 15 participants; 1 study; <a href="./references#CD011286-fig-0010" title="">Analysis 1.7</a>: RR 2.10, 95% CI 0.10 to 44.40; P = 0.63; 15 participants; 1 study; <a href="./references#CD011286-fig-0011" title="">Analysis 1.8</a>: RR 0.14, 95% CI 0.01 to 2.49; P = 0.18; 15 participants; 1 study). </p> <p>The participant who experienced manic symptoms, on day 19 of treatment with SAMe, was noted to be energetic, talkative, irritable, grandiose and hyperkinetic; his clinical ratings had improved dramatically, but he was noting the return of insomnia and decreased appetite. This 65‐year‐old white man completed the three‐week long trial and subsequently developed a manic episode characterised by pressured speech, flight of ideas, poor judgement, extensive travel, insomnia, decreased appetite, weight loss and expenditure of large sums of money. His manic episode persisted even though SAMe treatment had been discontinued three months earlier. The participant's history revealed only one prior depressive episode (responsive to doxepin), no prior history of mania on hypomania and a family history of depression but not mania. </p> <p>In both studies, there were no explicit reports of mortality during the treatment period (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). Overall, the trials did not systematically assess risk for suicidal ideation and behaviours. Neither study mentioned measurement of homocysteinaemia. </p> </section> <section id="CD011286-sec-0111"> <h6 class="title">1.8 Acceptability. Participants dropping out for any reasons other than adverse effects</h6> <p>There was no evidence of a difference between SAMe and placebo as monotherapy in terms of drop‐outs for any reason other than adverse effects (RR 0.91, 95% CI 0.60 to 1.38; P = 0.66; 142 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011286-fig-0012" title="">Analysis 1.9</a>). </p> </section> </section> </section> <section id="CD011286-sec-0112"> <h4 class="title">Comparison 2: S‐adenosyl methionine versus tricyclic antidepressant as monotherapy</h4> <p>Five studies were eligible for this comparison (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). See <a href="./full#CD011286-tbl-0002">summary of findings Table 2</a>. </p> <p>The <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias and at low risk of attrition, reporting and other bias. The <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study was at high risk of attrition bias, at unclear risk of selection bias and at low risk of bias in the remaining domains. Three studies were at unclear risk of selection, performance, detection and attrition bias, and at low risk of reporting and other bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). </p> <p>The antidepressant used as comparators in the included studies were imipramine and desipramine. </p> <section id="CD011286-sec-0113"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0114"> <h6 class="title">2.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>In this analysis, a reduction of depression rating scale score (indicated by a negative sign) represents an improvement. </p> <p>The overall analysis showed that the efficacy of SAMe as monotherapy in the treatment of depression was not different from that of imipramine (SMD ‐0.04, 95% CI ‐0.34 to 0.27; P = 0.82; 619 participants; 4 studies; I<sup>2</sup> = 57%) (<a href="./references#CD011286-fig-0013" title="">Analysis 2.1</a>). The evidence contributing to this outcome was low quality. </p> <p>One study favoured SAMe over the active antidepressant (imipramine) and was likely responsible for the heterogeneity between the studies (I<sup>2</sup> = 57%; P = 0.07) (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>). </p> </section> <section id="CD011286-sec-0115"> <h6 class="title">2.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>There was no evidence of a difference between SAMe and TCAs (imipramine and desipramine) with regard to drop‐outs during the study period for any reason (RR 0.61, 95% CI 0.28 to 1.31; P = 0.2; 78 participants; 3 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011286-fig-0014" title="">Analysis 2.2</a>). The evidence contributing to this outcome was very low quality. </p> </section> <section id="CD011286-sec-0116"> <h6 class="title">2.3 Acceptability. Participants dropping out of treatment during study period because of adverse effects </h6> <p>There was no evidence of a difference identified between drop‐outs because of adverse effects with SAMe as monotherapy versus imipramine (RR 0.75, 95% CI 0.20 to 2.79; P = 0.67; 52 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011286-fig-0015" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD011286-sec-0117"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0118"> <h6 class="title">2.4 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>In this analysis, an increase of RR represents a response to treatment in the SAMe group. </p> <p>There was no strong evidence of a difference in the response rate between SAMe and a TCA agent (imipramine and desipramine) as monotherapy (RR 1.14, 95% CI 0.83 to 1.56; P = 0.42; 622 participants; 4 studies; I<sup>2</sup> = 58%) (<a href="./references#CD011286-fig-0016" title="">Analysis 2.4</a>). The evidence contributing to this outcome was very low quality. </p> <p>We identified moderate heterogeneity among the studies (I<sup>2</sup> = 58%; P = 0.07), which has been investigated in the <a href="#CD011286-sec-0176">Discussion</a>. </p> </section> <section id="CD011286-sec-0119"> <h6 class="title">2.5 Efficacy. Remission, defined as a depression rating scale score within the normal range at end of study </h6> <p>There were no available data.</p> <p>One study provided details on remission for the four participants with psychotic features: the two participants in the experimental group were fully recovered by the end of the study, both having a HAM‐D score of less than 10; however, the two participants in the control group did not show remission (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>). </p> </section> <section id="CD011286-sec-0120"> <h6 class="title">2.6 Acceptability. Participants experiencing troublesome adverse effects of any nature</h6> <p>There was evidence of low quality that, compared to imipramine, treatment with SAMe decreased the risk of experiencing troublesome adverse effects of any nature by 30% (RR 0.68, 95% CI 0.52 to 0.88; P = 0.004; 604 participants; 3 studies) (<a href="./references#CD011286-fig-0017" title="">Analysis 2.5</a>). </p> <p>We identified moderate heterogeneity (I<sup>2</sup> = 32%) between the studies that was not significant (P = 0.23) and was probably due to the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> trial, which was the only one with the CI including 'no effect'. This study has a considerably smaller sample size than the other two; its removal from the analysis resulted in the elimination of the heterogeneity. </p> </section> <section id="CD011286-sec-0121"> <h6 class="title">2.7 Acceptability. Participants experiencing specific adverse effects identified in protocol </h6> <p>Only one study detailed adverse effects (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992)</a>. In the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study, it was just reported that none of the participants became manic during the trial. The <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study reported nausea and vomiting in six of the 15 participants in the SAMe group and in one of the 15 participants in the imipramine group, but we could not use these data in the analysis as these two symptoms were not reported separately. None of the participants reported headache, diarrhoea or flatulence. One participant exhibited hypomania in the SAMe arm (RR 3.00, 95% CI 0.13 to 68.26; P = 0.49; 48 participants; 2 studies) (<a href="./references#CD011286-fig-0018" title="">Analysis 2.6</a>). </p> <p>In all studies, there were no explicit reports of mortality. Overall, the trials did not systematically assess and report the risk for suicidal ideation and behaviours. None of the studies mentioned measurement of homocysteinaemia. </p> </section> <section id="CD011286-sec-0122"> <h6 class="title">2.8 Acceptability. Participants dropping out for any reasons other than adverse effects</h6> <p>There was no evidence that SAMe as monotherapy was more acceptable than a treatment with imipramine in terms of drop‐outs due to any reasons other than adverse effects (RR 1.00, 95% CI 0.17 to 5.89; P = 1; 52 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD011286-fig-0019" title="">Analysis 2.7</a>). </p> </section> </section> </section> <section id="CD011286-sec-0123"> <h4 class="title">Comparison 3: S‐adenosyl methionine versus selective serotonin reuptake inhibitor as monotherapy </h4> <p>One study was eligible for this comparison (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). See <a href="./full#CD011286-tbl-0003">summary of findings Table 3</a>. </p> <p>The included study was at unclear risk of attrition bias and at low risk of bias in the other domains. </p> <p>The antidepressant used as comparator was escitalopram.</p> <section id="CD011286-sec-0124"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0125"> <h6 class="title">3.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>In this analysis, lowering of a depression rating scale score (indicated by a negative sign) represents an improvement. </p> <p>The analysis showed that there was no evidence of a difference in mean depression rating change scores between SAMe and escitalopram, both as monotherapy (MD 0.12, 95% CI ‐2.75 to 2.99; P = 0.93; 129 participants; 1 study) (<a href="./references#CD011286-fig-0020" title="">Analysis 3.1</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0126"> <h6 class="title">3.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>There was no evidence of a difference between SAMe and escitalopram with regard to drop‐outs during the study period for any reason (RR 0.81, 95% CI 0.57 to 1.16; P = 0.26; 129 participants; 1 study) (<a href="./references#CD011286-fig-0021" title="">Analysis 3.2</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0127"> <h6 class="title">3.3 Acceptability. Participants dropping out of treatment during study period because of adverse effects </h6> <p>There was no evidence of a difference identified between drop‐outs because of adverse effects with SAMe as monotherapy versus escitalopram (RR 0.38, 95% CI 0.11 to 1.37; P = 0.14; 129 participants; 1 study) (<a href="./references#CD011286-fig-0022" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD011286-sec-0128"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0129"> <h6 class="title">3.4 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>In this analysis, an increase of RR represents a positive outcome indicating response to treatment in the SAMe group. </p> <p>There was no evidence of a difference in the response rate between SAMe and escitalopram as monotherapy (RR 1.06, 95% CI 0.66 to 1.70; P = 0.8; 129 participants; 1 study) (<a href="./references#CD011286-fig-0023" title="">Analysis 3.4</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0130"> <h6 class="title">3.5 Efficacy. Remission, defined as a depression rating scale score within the normal range at end of study </h6> <p>In this analysis, an increase of RR represents a positive outcome indicating response to treatment in the SAMe group. </p> <p>There was no evidence that SAMe was more efficacious than an active antidepressant agent in reaching the remission from depression (RR 1.02, 95% CI 0.58 to 1.77; P = 0.96; 129 participants; 1 studies) (<a href="./references#CD011286-fig-0024" title="">Analysis 3.5</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0131"> <h6 class="title">3.6 Acceptability. Participants experiencing troublesome adverse effects of any nature</h6> <p>There were no available data for this outcome.</p> </section> <section id="CD011286-sec-0132"> <h6 class="title">3.7 Acceptability. Participants experiencing specific adverse effects identified in protocol </h6> <p>There were no available data for this outcome. There were no explicit reports of mortality reported. The study did not systematically assess and report the risk for suicidal ideation and behaviours. The study did not mention measurement of homocysteinaemia. </p> </section> <section id="CD011286-sec-0133"> <h6 class="title">3.8 Acceptability. Participants dropping out for any reasons other than adverse effects</h6> <p>There was no evidence that SAMe as monotherapy was more acceptable than a treatment with a SSRI antidepressant (escitalopram), in terms of drop‐outs due to any reasons other than adverse effects (RR 0.94, 95% CI 0.62 to 1.43; P = 0.77; 129 participants; 1 study) (<a href="./references#CD011286-fig-0025" title="">Analysis 3.6</a>). </p> </section> </section> </section> <section id="CD011286-sec-0134"> <h4 class="title">Comparison 4: S‐adenosyl methionine versus placebo as adjunctive treatment</h4> <p>One study compared SAMe with placebo as an adjunctive treatment to their existing SSRI treatment (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). See <a href="./full#CD011286-tbl-0004">summary of findings Table 4</a>. The study was at unclear risk of bias for random sequence generation and at low risk of bias in the other categories. </p> <p>This study examined a particular subgroup of participants with major depression, namely SSRI non‐responders. We planned to analyse this subgroup separately. However, as it was the only study in this comparison, this was not necessary. </p> <section id="CD011286-sec-0135"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0136"> <h6 class="title">4.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>In this analysis, lowering of a depression rating scale score (indicated by a negative sign) represents an improvement. </p> <p>There was low quality evidence that SAMe was superior to placebo as add‐on to SSRIs in terms of change in depressive symptoms from baseline to end of treatment (MD ‐3.90, 95% CI ‐6.93 to ‐0.87; P = 0.01; 73 participants; 1 study) (<a href="./references#CD011286-fig-0026" title="">Analysis 4.1</a>). </p> </section> <section id="CD011286-sec-0137"> <h6 class="title">4.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>There was no evidence of a difference between SAMe and placebo as adjunctive therapy with regard to drop‐outs during the study period for any reason (RR 0.70, 95% CI 0.31 to 1.56; P = 0.38; 73 participants; 1 study) (<a href="./references#CD011286-fig-0027" title="">Analysis 4.2</a>). The evidence contributing to this outcome was very low quality. </p> </section> <section id="CD011286-sec-0138"> <h6 class="title">4.3 Acceptability. Participants dropping out of treatment during study period because of adverse effects </h6> <p>There was no evidence of a difference between SAMe and placebo as adjunctive therapy with regard to drop‐outs during the study period because of adverse effects (RR 0.58, 95% CI 0.10 to 3.28; P = 0.54; 73 participants; 1 study) (<a href="./references#CD011286-fig-0028" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD011286-sec-0139"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0140"> <h6 class="title">4.4 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>In this analysis, positive RR represents a positive outcome indicating response to treatment in the SAMe group. </p> <p>We found evidence that the number of participants in the SAMe arm who obtained a reduction of 50% or greater in depression score was significantly higher than in the placebo arm (RR 2.62, 95% CI 1.17 to 5.83; P = 0.02; 73 participants; 1 study) (<a href="./references#CD011286-fig-0029" title="">Analysis 4.4</a>). The evidence contributing to this outcome was low quality. </p> </section> <section id="CD011286-sec-0141"> <h6 class="title">4.5 Efficacy. Remission, defined as a depression rating scale score within the normal range at end of study </h6> <p>In this analysis, an increase of RR represents a positive outcome indicating response to treatment in the SAMe group. </p> <p>For every person in the placebo group that achieved remission, three people in the SSRI/SAMe achieved remission although obviously alongside the caveat that this is based on only study that was low quality due to indirectness and imprecision (RR 3.05, 95% CI 1.11 to 8.39; P = 0.03; 73 participants; 1 study) (<a href="./references#CD011286-fig-0030" title="">Analysis 4.5</a>). </p> </section> <section id="CD011286-sec-0142"> <h6 class="title">4.6 Acceptability. Participants experiencing troublesome adverse effects of any nature</h6> <p>There was no available data for this outcome.</p> </section> <section id="CD011286-sec-0143"> <h6 class="title">4.7 Acceptability. Participants experiencing specific adverse effects identified in protocol </h6> <p>The authors of the study reported only those adverse effects experienced by at least two participants, and so we could not include the study in the quantitative analysis of the all specific adverse effects. The study reported headache and diarrhoea; neither were significantly different compared with the placebo group (headache: RR 1.74, 95% CI 0.34 to 8.93; P = 0.50; 73 participants; 1 study; <a href="./references#CD011286-fig-0031" title="">Analysis 4.6</a>; diarrhoea: RR 1.22, 95% CI 0.43 to 3.49; P = 0.71; 73 participants; 1 study; <a href="./references#CD011286-fig-0032" title="">Analysis 4.7</a>). </p> <p>There were no explicit reports of mortality during the study period. Overall, the trials did not systematically assess and report risk for suicidal ideation and behaviours. The study did not mention measurement of homocysteinaemia. </p> </section> <section id="CD011286-sec-0144"> <h6 class="title">4.8 Acceptability. Participants dropping out for any reasons other than adverse effects</h6> <p>The number of drop‐outs for any reasons other than adverse effects was not significantly different between the two arms (RR 0.75, 95% CI 0.28 to 2.01; P = 0.56; 73 participants; 1 study) (<a href="./references#CD011286-fig-0033" title="">Analysis 4.8</a>). </p> </section> </section> </section> <section id="CD011286-sec-0145"> <h4 class="title">Subgroup analyses</h4> <p>We conducted subgroup analyses only on data from parenteral and oral administration of SAMe. </p> <p>We planned to perform other subgroup analyses but it was not possible, as explained below. </p> <p>One study described psychotic symptoms in four participants (two in each treatment group) (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>); however, because it was impossible to separate data from these participants, a subgroup analysis was not undertaken. The authors commented that the two participants in the SAMe group who experienced major depression with psychotic features (somatic/nihilistic delusions) were fully recovered by the end of the study and each had a HAM‐D score of less than 10; both of the participants treated with imipramine with psychotic features did not respond to imipramine only. Six studies excluded participants who had psychotic symptoms (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). </p> <p>No studies provided data regarding a specific group of participants with atypical depression or with anxiety symptoms. However, one study used the augmented 31‐item HAM‐D (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>). This scale added items that identified atypical depressive symptoms such as hyperphagia; hypersomnia; psychomotor retardation; and feelings of helplessness, hopelessness and worthlessness; in addition, the individual item anxiety on the same depression scale was pointed out. The authors commented that between‐group comparison of scores for individual items on the HAM‐D at the endpoint demonstrated a significantly greater improvement for participants treated with SAMe than participants treated with imipramine on items concerning psychic anxiety, helplessness, worthlessness and hypersomnia. One study evaluated participants using the 14‐item Hamilton Rating Scale for Anxiety (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>); the authors commented that at the endpoint, there was a significant difference versus baseline values on this scale in both treatment groups. </p> <p>One study examined a particular subgroup of participants with major depression, namely SSRI non‐responders (<a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). We planned to analyse this subgroup separately. However, as it was the only study under the appropriate comparison, we did not perform a subgroup analysis. </p> <section id="CD011286-sec-0146"> <h5 class="title">Comparison: S‐adenosyl methionine versus tricyclic antidepressant as monotherapy</h5> </section> <section id="CD011286-sec-0147"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0148"> <h6 class="title">5.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>The subgroup analyses on data from oral and parenteral administration of SAMe yielded similar results (oral: SMD 0.06, 95% CI ‐0.17 to 0.28; P = 0.62; 303 participants; 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD011286-fig-0041" title="">Analysis 6.1</a>; parenteral: SMD ‐0.46, 95% CI ‐1.68 to 0.75; P = 0.45; 316 participants; 2 studies; I<sup>2</sup> = 85%; <a href="./references#CD011286-fig-0042" title="">Analysis 6.2</a>). </p> </section> <section id="CD011286-sec-0149"> <h6 class="title">5.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>Considering data from oral and parenteral administration of SAMe separately, the lack of significant difference between SAMe and active antidepressant persisted (oral: RR 0.54, 95% CI 0.23 to 1.27; P = 0.16; 56 participants; 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD011286-fig-0043" title="">Analysis 6.3</a>; parenteral: RR 1.00, 95% CI 0.17 to 5.89; P = 1; 22 participants; 1 study; I<sup>2</sup> = 0%; <a href="./references#CD011286-fig-0044" title="">Analysis 6.4</a>). We noted that in <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>, of the 11 participants treated with intravenous SAMe, two refused to continue the study because of the discomfort of the intravenous procedure. </p> </section> <section id="CD011286-sec-0150"> <h6 class="title">5.3 Acceptability. Participants dropping out of treatment during study period because of adverse effects </h6> <p>The subgroup analyses on data from oral and parenteral administration of SAMe did not change the results and neither of the methods of administration differed from the two combined (oral: RR 0.75, 95% CI 0.20 to 2.79; P = 0.67; 30 participants; 1 study; I<sup>2</sup> = 0%; <a href="./references#CD011286-fig-0045" title="">Analysis 6.5</a>; parenteral: no events; <a href="./references#CD011286-fig-0046" title="">Analysis 6.6</a>). </p> </section> </section> <section id="CD011286-sec-0151"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0152"> <h6 class="title">5.4 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>When we conducted the subgroup analysis separating data from oral and parenteral administration, the outcome was not affected (oral: RR 1.35, 95% CI 0.44 to 4.09; P = 0.6; 306 participants; 2 studies; I<sup>2</sup> = 64%; <a href="./references#CD011286-fig-0047" title="">Analysis 6.7</a>; parenteral: RR 1.46, 95% CI 0.66 to 3.26; P = 0.35; 316 participants; 2 studies; I<sup>2</sup> = 46%; <a href="./references#CD011286-fig-0048" title="">Analysis 6.8</a>), and neither of the methods of administration differed from the two combined. </p> </section> <section id="CD011286-sec-0153"> <h6 class="title">5.5 Acceptability. Participants experiencing troublesome adverse effects of any nature</h6> <p>When we considered separately data from oral and parenteral administration of SAMe, we found evidence for better acceptability was found only for the parenteral administration (RR 0.59, 95% CI 0.44 to 0.78; P = 0.0002; 294 participants; 1 study; I<sup>2</sup> = 0%; <a href="./references#CD011286-fig-0049" title="">Analysis 6.9</a>). The analysis of the data regarding the oral administration of SAMe showed no significant difference between the two groups (RR 0.80, 95% CI 0.50 to 1.27; P = 0.34; 310 participants; 2 studies; I<sup>2</sup> = 40%; <a href="./references#CD011286-fig-0050" title="">Analysis 6.10</a>). In this last case, one out of the two studies contributing to the outcome, only one favoured SAMe in terms of acceptability. The two studies were heterogeneous in terms of sample size (180 participants <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; 30 participants <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). Further, in the <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a> study, in participants who complained of adverse effects, the drug dose could be reduced from the third week onward, to a minimum dose of imipramine 100 mg/day and SAMe 1200 mg/day. This could mean that a dose reduction of SAMe may minimise the risk of experiencing adverse effects more than a reduction of imipramine. </p> </section> <section id="CD011286-sec-0154"> <h6 class="title">5.6 Acceptability. Participants dropping out for any reasons other than adverse effects</h6> <p>When we considered data from oral and parenteral administration of SAMe separately, the outcome was not affected and neither of the methods of administration differed from the two combined (oral: no events; <a href="./references#CD011286-fig-0051" title="">Analysis 6.11</a>; parenteral: RR 1.00, 95% CI 0.17 to 5.89; P = 1; 22 participants; 1 study; I<sup>2</sup> = 0%; <a href="./references#CD011286-fig-0052" title="">Analysis 6.12</a>). </p> </section> </section> </section> <section id="CD011286-sec-0155"> <h4 class="title">Sensitivity analyses</h4> <p>In the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study, we extrapolated the data regarding the efficacy of treatment from the figure reported in the paper, as no other information was available. To check the correctness of our calculations, we verified if the extrapolated MD matched with the per cent improvement in the mean scores shown in the paper. In addition, the authors did not specify how they dealt with missing data. We attempted to contact them in order to obtain clarification, but were unsuccessful. As they did not indicate whether they had or not conducted an ITT analysis, we decided to use only the reported data without any imputation, in order to be the most conservative possible. To assess the robustness of these assumptions, we conducted a sensitivity analysis. </p> <p>We identified two studies with more than 30% of missing data and carried out a sensitivity analysis (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). Further, as two studies provided no drop‐outs rates, we decided to exclude these studies in this sensitivity analysis (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>). </p> <p>The <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study was at high risk of attrition bias; we performed a sensitivity analysis excluding this study. </p> <p>Further, we conducted a sensitivity analysis where we had imputed missing data and standard deviations. </p> <section id="CD011286-sec-0156"> <h5 class="title">Comparison 1: S‐adenosyl methionine versus placebo as monotherapy</h5> </section> <section id="CD011286-sec-0157"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0158"> <h6 class="title">6.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>When we performed a sensitivity analysis excluding the <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> trial (more than 30% missing data), the results with the remaining data from <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> were significantly different (<a href="./references#CD011286-fig-0037" title="">Analysis 5.4</a>). However, it is important to remember that the <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> study had a very small sample size (18 participants). </p> <p>Otherwise, the other conducted sensitivity analyses did not affect the results (sensitivity analysis for the imputation of continuous efficacy data with the assumption that missing participants had the same mean change as the other participants, <a href="./references#CD011286-fig-0034" title="">Analysis 5.1</a>; sensitivity analysis for the imputation of standard deviations, using correlation coefficient of 0.4, <a href="./references#CD011286-fig-0036" title="">Analysis 5.3</a>). </p> </section> <section id="CD011286-sec-0159"> <h6 class="title">6.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>The sensitivity analysis excluding the study with high levels of missing data (<a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>) did not change the result, although only one study remained (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>) (<a href="./references#CD011286-fig-0038" title="">Analysis 5.5</a>). </p> </section> </section> <section id="CD011286-sec-0160"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0161"> <h6 class="title">6.3 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>We performed two sensitivity analyses: sensitivity analysis for the imputation of dichotomous data with the assumption of 'best‐case' scenario (<a href="./references#CD011286-fig-0035" title="">Analysis 5.2</a>), and sensitivity analysis excluding study with high levels of missing data (<a href="./references#CD011286-fig-0039" title="">Analysis 5.6</a>). In both cases, the results were not affected. </p> </section> <section id="CD011286-sec-0162"> <h6 class="title">6.4 Acceptability. Participants dropping out for any reasons other than adverse effects</h6> <p>The sensitivity analysis excluding <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> (high level of missing data) had only one study and did not affect the results (<a href="./references#CD011286-fig-0040" title="">Analysis 5.7</a>). </p> </section> </section> <section id="CD011286-sec-0163"> <h5 class="title">Comparison 2: S‐adenosyl methionine versus tricyclic antidepressant as monotherapy</h5> </section> <section id="CD011286-sec-0164"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0165"> <h6 class="title">7.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>We conducted the following sensitivity analyses, which did not affect the results: sensitivity analysis for the imputation of continuous efficacy data with the assumption that missing participants had the same mean change as the other participants (<a href="./references#CD011286-fig-0053" title="">Analysis 6.13</a>); sensitivity analysis for the imputation of standard deviations using correlation coefficient of 0.4 (<a href="./references#CD011286-fig-0055" title="">Analysis 6.15</a>); sensitivity analysis excluding studies with high levels of missing data (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>) (<a href="./references#CD011286-fig-0056" title="">Analysis 6.16</a>); sensitivity analysis excluding the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study (<a href="./references#CD011286-fig-0060" title="">Analysis 6.20</a>). </p> </section> <section id="CD011286-sec-0166"> <h6 class="title">7.2 Acceptability. Participants dropping out of treatment during study period for any reason </h6> <p>The sensitivity analysis excluding studies with high levels of missing data (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>) (<a href="./references#CD011286-fig-0057" title="">Analysis 6.17</a>) and the sensitivity analysis excluding the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study that was at high risk of attrition bias (<a href="./references#CD011286-fig-0061" title="">Analysis 6.21</a>) did not change the results. </p> </section> </section> <section id="CD011286-sec-0167"> <h5 class="title">Secondary outcomes</h5> <section id="CD011286-sec-0168"> <h6 class="title">7.3 Efficacy. Response to treatment, defined as a 50% reduction or greater in depression score from baseline to end of treatment </h6> <p>We carried out the sensitivity analyses as per protocol: sensitivity analysis for the imputation of dichotomous data with the assumption of 'best‐case' scenario (<a href="./references#CD011286-fig-0054" title="">Analysis 6.14</a>); sensitivity analysis excluding studies with high levels of missing data (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>) (<a href="./references#CD011286-fig-0058" title="">Analysis 6.18</a>); sensitivity analysis excluding the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study that was at high risk of attrition bias (<a href="./references#CD011286-fig-0062" title="">Analysis 6.22</a>). This did not change the results. </p> </section> <section id="CD011286-sec-0169"> <h6 class="title">7.4 Acceptability. Participants experiencing troublesome adverse effects of any nature</h6> <p>When we performed a sensitivity analysis excluding studies with high levels of missing data (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>), only the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study remained. The results changed and we found no evidence of SAMe superiority (<a href="./references#CD011286-fig-0059" title="">Analysis 6.19</a>). </p> </section> </section> <section id="CD011286-sec-0170"> <h5 class="title">Comparison 3: S‐adenosyl methionine versus selective serotonin reuptake inhibitor as monotherapy </h5> </section> <section id="CD011286-sec-0171"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0172"> <h6 class="title">8.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>We conducted a sensitivity analysis for the imputation of standard deviations using correlation coefficient of 0.4, which did not affect the results (<a href="./references#CD011286-fig-0063" title="">Analysis 7.1</a>). </p> </section> </section> <section id="CD011286-sec-0173"> <h5 class="title">Comparison 4: S‐adenosyl methionine versus placebo as adjunctive treatment</h5> </section> <section id="CD011286-sec-0174"> <h5 class="title">Primary outcomes</h5> <section id="CD011286-sec-0175"> <h6 class="title">9.1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale </h6> <p>We performed a sensitivity analysis to assess the robustness of the imputation of standard deviations using a correlation coefficient of 0.4 (<a href="./references#CD011286-fig-0064" title="">Analysis 8.1</a>). The outcome was not affected. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011286-sec-0176" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011286-sec-0176"></div> <section id="CD011286-sec-0177"> <h3 class="title" id="CD011286-sec-0177">Summary of main results</h3> <p>This systematic review included eight trials and 934 participants. The quality of the evidence, reflected in the GRADE analysis, ranged from low to very low. This limits the applicability of the findings and the interpretation of the treatment effects should be made with caution. </p> <p>We did not find that SAMe was more efficacious than placebo in monotherapy, reflected in mean change data in depression rating scale and in response and remission findings; there were two studies in the first two analyses and one study in the last analysis. These results should be interpreted with caution. The quality of the evidence contributing to these outcomes was low to very low. The result of these analyses were determined by data from a large three‐arm trial in which neither SAMe nor escitalopram were superior to placebo. Further, in <a href="./references#CD011286-fig-0004" title="">Analysis 1.1</a> (change in mean scores from baseline to end of treatment on the depression rating scale) the studies showed a high level of heterogeneity (I<sup>2</sup> = 72%; P = 0.06). The <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> study favoured SAMe over placebo in terms of efficacy (SMD ‐1.18; CI ‐2.21, ‐0.15; P = 0.02), but the <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> study reported no evidence that the active treatment was more efficacious than placebo (SMD ‐0.13; CI ‐0.48 to 0.22; P = 0.46). This heterogeneity could be related to the different duration of the trials (three weeks, <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; 12 weeks, <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>). As the risk of spontaneous improvement is cumulative (<a href="./references#CD011286-bbs2-0104" title="PosternakMA , ZimmermannM . Short‐term spontaneous improvement rates in depressed outpatients. Journal of Nervous and Mental Disease2000;188(12):799‐804. ">Posternak 2000</a>), it could be maximised in a 12‐week trial, increasing the placebo response. However, it is noted that in the <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> study, there was significant separation between SAMe and placebo on the depression rating scale only at treatment at weeks eight and 10, not at week three and dose increase was allowed for non‐responders at week six. It is also noted that in <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>, a three‐armed study comparing placebo, SAMe and escitalopram, at the endpoint, all three treatments arms demonstrated a significant improvement in the depression rating scale but there was no significant difference between any of the treatments. Another potential source of heterogeneity could be that different formulations of SAMe may have been used: <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> used SAMe tosylate, while <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> did not specify the formulation. Another source of heterogeneity could be that participants in <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> trial were all inpatients while in <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> trial they were all outpatients; this could suggest a different severity of the disease. In addition, one study recruited only men (<a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>), while <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> recruited both men and women, raising the issue of a possible gender effect of SAMe (<a href="./references#CD011286-bbs2-0110" title="SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Sarris 2015a</a>). In addition, it is relevant that the two studies were highly diverged in terms of sample size: <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a> had the largest number of participants (124), but also had a high level of missing data. </p> <p>SAMe was more efficacious than placebo as an adjunctive treatment, using mean change data and in terms of response and remission. The quality of this evidence was low. Only one small study contributed to these outcomes, only SSRIs were tested as an add‐on therapy and the data regarded a specific subgroup of participants (SSRI non‐responders). </p> <p>We did not find the efficacy of SAMe as monotherapy to be different from that of TCA and SSRI antidepressants in the treatment of depression, using mean change data and response/remission findings; four studies were in the comparison SAMe versus TCAs and one study in the comparison SAMe versus SSRI. There was a very small selection of antidepressants tested: the TCAs imipramine and desipramine, and the SSRI escitalopram. In addition, the quality of the evidence contributing to outcomes was low or very low. Under the comparison of SAMe versus a TCA for the mean change score outcome, the studies involved in the analysis were heterogeneous (I<sup>2</sup> = 57%; P = 0.07). One study favoured SAMe over imipramine (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>). This could be due to its shorter duration (two weeks). In addition, the therapeutic action of imipramine is often delayed by two to four weeks, and these results may suggest a more rapid onset of action of the SAMe. Another potential source of heterogeneity could be that different formulations of SAMe could have been used: the <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a> and <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a> studies used butanedisulphonate‐SAMe, while the other trials did not specify formulations. In addition, the doses and routes of administration of SAMe among the studies varied. However, when we conducted subgroup analyses separating data regarding oral and parenteral administration of SAMe, neither of the methods of administration differed from the two combined and the outcome was not affected. Under the same comparison examining response, we identified moderate heterogeneity among the studies (I<sup>2</sup> = 58%; P = 0.07). The reasons above could explain this heterogeneity as well as the different comparator antidepressants used (even if there was no pattern of efficacy to explain the heterogeneity). </p> <p>Overall, the quality of the evidence related to acceptability outcomes was low or very low. </p> <p>We did not find any evidence that SAMe was more acceptable than antidepressant agents in terms of drop‐outs. For the comparison SAMe versus TCA, there were three studies in the analysis 'Participants dropping out of treatment during the study period for any reason' and two studies in the analysis 'Participants dropping out of the treatment during the study period because of adverse effects'; for the comparison SAMe versus SSRI, there was only one study. Interestingly, there was no strong evidence of a difference in rates of drop‐outs between SAMe and placebo; there were two studies in the analyses where SAMe and placebo were used as monotherapy, and one study in the analyses where SAMe and placebo were used as an adjunctive treatment. With the exception of the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study where all drop‐outs were caused by adverse effects, withdrawals were generally due to other causes such as clinical worsening, non‐adherence and scheduling. </p> <p>With regard to tolerability in terms of number of participants experiencing troublesome adverse effects of any nature, we found parenteral SAMe to be more tolerable than imipramine (three studies in this analysis). Data regarding tolerability of SAMe for the other comparison were not available; however, the studies reported in the text that SAMe was overall safe and well‐tolerated. </p> <p>Most studies did not detail the specific adverse effects or they were often described with considerable heterogeneity, precluding a complete quantitative analysis of these data. Therefore, no definitive conclusions can be drawn on this issue. Using the available data, we found no evidence of a difference between SAMe and the comparisons with regard to the specific adverse effects of headache, diarrhoea and flatulence (only one study and a very small number of participants were included in each analyses). With regard to mania/hypomania, the analyses involved two studies: in one study, one participant exhibited hypomania and in another study, one participant with no prior history of mania experienced manic symptoms, both while taking SAMe. There were no explicit reports of mortality. Overall, the trials did not systematically assess and report risk for suicidal ideation and behaviours. </p> <p>The parenteral and oral administration of SAMe seemed to be comparable. Trials used lower doses for parenteral administration than oral. This probably reflects the better bioavailability of SAMe when given parenterally (<a href="./references#CD011286-bbs2-0114" title="StramentinoliG , GualanoM , Galli‐KienzleM . Intestinal absorption of S‐adenosyl‐L‐methionine. Journal of Pharmacology and Experimental Therapeutics1979;209:323‐6. ">Stramentinoli 1979</a>). However, the specific dose equivalence between the oral and parenteral routes of administration of SAMe is not established yet. </p> </section> <section id="CD011286-sec-0178"> <h3 class="title" id="CD011286-sec-0178">Overall completeness and applicability of evidence</h3> <p> <ol id="CD011286-list-0011"> <li> <p>This systematic review included only RCTs and they were similar in design. They differed in duration of treatment, routes of administration and sample size. The assessment of the quality of the trials was often hindered by the lack of detail regarding key methodological issues, such as randomisation, allocation concealment, blinding and missing data. </p> </li> <li> <p>The number of included studies, the number of trials used in each comparison, and, in general, the number of participants in those studies were small. Although all the objectives of the review were addressed (see <a href="#CD011286-sec-0028">Objectives</a>), not all studies provided appropriate data for all the outcomes we considered. In addition, for some outcomes the CIs were large. These factors limit the applicability of the findings and the interpretation of the treatment effects. </p> </li> <li> <p>The use of SAMe in the included studies reflects its use in practice. Trials tested standard doses and both oral and parenteral routes. However, in the clinical practice lower doses of SAMe are also administered for the oral route (800 mg/day to 1200 mg/day as per leaflet of the commercialised drug). </p> </li> <li> <p>Studies analysed both men and women with a diagnosis of major depression according to DSM‐III or DSM‐IV criteria, the population of interest for this review. However, with the exception of one study examining a particular subgroup of participants with major depression (SSRI non‐responders), we could not obtain data from other subgroup of participants such as with atypical depression or anxiety symptoms or psychotic symptoms or with treatment resistance. Therefore, we could not investigate if participants with certain subtypes of depression may respond differently to SAMe. We also excluded participants with bipolar depression, schizoaffective disorder, cyclothymia and dysthymia; therefore, the results cannot be generalised to depressive episodes occurring in these contexts. Overall, it is accepted that one of the main limitations of efficacy trials is to include participants far from "real world" (<a href="./references#CD011286-bbs2-0107" title="RothwellPM . External validity of randomised controlled trials: to whom do the results apply?. Lancet2005;365:82‐93. ">Rothwell 2005</a>). In clinical practice, patients are usually very heterogeneous, even among groups of people with the same diagnosis. Similarly, in clinical practice a large proportion of people with depression have physical comorbidities. As we excluded studies of participants with physical comorbidities, this further limits the generalisability of the findings. This issue may be considered in a future version of this review. </p> </li> <li> <p>We found SAMe to be more efficacious than placebo as an adjunctive treatment. However, the applicability of this evidence is limited. Only one trial contributed to the outcome, participants were only SSRI non‐responders and SAMe was added only to one category of antidepressant (the SSRI). Further, under the comparisons of SAMe versus an active treatment, overall studies included only three antidepressant agents (imipramine, escitalopram and desipramine), limiting the applicability of the evidence. </p> </li> <li> <p>The economic case for the use of SAMe in clinical practice cannot be made as the trials did not provide information on the comparative costs of the treatments. </p> </li> </ol> </p> </section> <section id="CD011286-sec-0179"> <h3 class="title" id="CD011286-sec-0179">Quality of the evidence</h3> <p>We assessed the quality of evidence and constructed the 'Summary of findings' tables for each comparison. See <a href="./full#CD011286-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011286-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011286-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011286-tbl-0004">summary of findings Table 4</a>. </p> <p>From the GRADE evaluation documented in the 'Summary of findings' tables, this systematic review found no evidence of high or moderate quality. The quality of the evidence for SAMe was generally low/very low. </p> <p>It is concluded that higher quality evidence from further research would be required to increase our confidence in the estimate of the effect of this intervention. We rated the quality of the body of evidence for the outcomes accounting the following factors: risk of bias, inconsistency, indirectness, imprecision and publication bias. </p> <p>All included studies were RCTs. However, often, we were unable to assess the quality of the trials because of the lack of information regarding randomisation, allocation concealment, blinding and missing data (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>; <a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>). On addition, one of the included studies had a high risk of attrition bias (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). We downgraded, for risk of bias, the quality of evidence by one level for the outcomes determined by these studies. </p> <p>We downgraded, for inconsistency, the evidence for the outcomes where the contributing studies showed a significant heterogeneity (P &lt; 0.1). </p> <p>We downgraded the evidence for the outcomes where the <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a> study was a contributor, because of indirectness. This trial examined a particular subgroup of participants with major depression, namely SSRI non‐responders. </p> <p>In most outcomes, we downgraded the quality of evidence for imprecision because the sample size was small, the number of relevant events was small and the CIs were wide and included 'no effect'. </p> <p>In accordance with the protocol, we did not formally assess publication bias by funnel plot analyses, because the review included fewer than 10 studies (<a href="./references#CD011286-bbs2-0119" title="GaliziaI , OldaniL , MacritchieK , AmariE , DougallD , JonesTN , et al. S‐adenosyl methionine (SAM‐e) for depression in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011286] ">Galizia 2014</a>). </p> </section> <section id="CD011286-sec-0180"> <h3 class="title" id="CD011286-sec-0180">Potential biases in the review process</h3> <p>Some limitations and biases could be noted in the review process.</p> <p> <ol id="CD011286-list-0012"> <li> <p>We performed a broad and thorough literature search, exploring all sources detailed in the protocol (<a href="./references#CD011286-bbs2-0119" title="GaliziaI , OldaniL , MacritchieK , AmariE , DougallD , JonesTN , et al. S‐adenosyl methionine (SAM‐e) for depression in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011286] ">Galizia 2014</a>). Therefore, it is likely that we identified all relevant studies. However, it is possible that we missed studies that are still unpublished or are currently being conducted and plan to include these in future updates of the review. Then, although we made exhaustive attempts to retrieve as much data as possible, by asking pharmaceutical companies and study authors to supply all available information, data from some trials are still lacking. Further, this review lists a number of references and one study classified as 'awaiting classification', apparently published but proved unretrievable. </p> </li> <li> <p>All included studies were RCTs. However, the assessment of the trial quality was often complicated by the lack of information regarding randomisation, allocation concealment, blinding and missing data. Further, some of the older included studies did not reflect current methodological practice. </p> </li> <li> <p>Overall, the included studies did not always report the data we needed to assess all our outcomes. For example, only a few studies reported detailed data on the specific adverse effects occurring during the trials as well as the rates of adverse effects of any nature experienced by participants. </p> </li> <li> <p>The meta‐analyses often combined data from studies of different durations and routes of medication administration. Where identified, we investigated heterogeneity and conducted subgroup analyses if possible. </p> </li> <li> <p>In the case of missing data, we analysed data on an ITT basis. Some of the studies included data from 'completer' data‐sets only. Although we contacted the trialists, attempts to obtain additional unpublished data and information regarding missing data were almost always unsuccessful. We were unable to use the LOCF approach for dealing with missing data, as individual raw participant data were not available. Therefore, where needed, we imputed the missing data as well as the standard deviations. Although the sensitivity analyses conducted to assess the robustness of the assumptions yielded similar results, the imputation may have led to biases. </p> </li> <li> <p>Although all included studies evaluated the efficacy of treatment by administration of the HAM‐D, they used different versions of this rating scale. Therefore, we had to apply the SMD in order to measure the treatment efficacy and this could have led to some biases. </p> </li> <li> <p>We evaluated both the rates of response to treatment and the remission. 'Treatment response' describes an improvement in the person's condition of sufficient quality to result in a reduction of at least 50% in depressive symptomatology. However, what is clinically relevant is achieving remission, which correlates with better longer‐term functional recovery and lower risk of relapse. Only two studies in this review reported remission rates. </p> </li> <li> <p>Three studies provided participants over the age range of our review, including participants aged 18 to 80 years (<a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>; <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>; <a href="./references#CD011286-bbs2-0008" title="MischoulonD , AlpertJE , ArningE , BottiglieriT , FavaM , PapakostasGI . Bioavailability of S‐adenosyl methionine and impact on response in a randomized, double‐blind, placebo‐controlled trial in major depressive disorder [NCT00093847]. Journal of Clinical Psychiatry2012;73(6):843‐8. PapakostasGI . S‐Adenosyl methionine (SAMe) augmentation of selective serotonin reuptake inhibitors (SSRIs) for treatment‐resistant depression (TRD). clinicaltrials.gov/show/NCT00093847 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00093847] PapakostasGI , MischoulonD , ShyuI , AlpertJE , FavaM . S‐adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double‐blind, randomized clinical trial. American Journal of Psychiatry2010;167(8):942‐8. ">Papakostas 2010a</a>). Our protocol restricted the age range to 18 to 70 years but did not stipulate methods for how to deal with this issue (<a href="./references#CD011286-bbs2-0119" title="GaliziaI , OldaniL , MacritchieK , AmariE , DougallD , JonesTN , et al. S‐adenosyl methionine (SAM‐e) for depression in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011286] ">Galizia 2014</a>). We decided to include these studies after consideration of the mean age of the participants. </p> </li> <li> <p>One study was not designed to test efficacy of SAMe as a primary outcome, but focused on the correlation between plasma SAMe levels and the degree of clinical improvement (<a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a>). In this study, a subset of participants from a previously reported double‐blind study comparing oral SAMe and desipramine participated in the trial. Therefore, though the study included data for efficacy and tolerability, it may not have been sufficiently powered to detect differences in depressive symptoms. </p> </li> <li> <p>Another potential bias in the review process could come from the method in which data were obtained from the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study. We extrapolated data regarding the efficacy of treatment from the figure reported in the paper, as no other information was available. We checked the correctness of our calculations verifying that the extrapolated MDs matched the per cent improvement in the mean scores cited in the paper. In addition, the authors of this study did not specify how they dealt with missing data. We attempted to contact authors to obtain clarification but were unsuccessful. As they did not indicate whether they had conducted an ITT analysis, we decided to use the reported data without any imputation. These factors could have led to bias, although the sensitivity analysis conducted yielded similar results. </p> </li> <li> <p>Some studies allowed the use of benzodiazepines as a hypnotic, but in none of the studies did the authors analyse its potential confounding effects. This could have led to bias in the included studies and so in this review. </p> </li> <li> <p>In the present review no RCTs reported economic outcomes. This represents a limit for the applicability of findings as comprehensive economic estimates of antidepressant treatment effect would better inform healthcare policy. </p> </li> </ol> </p> </section> <section id="CD011286-sec-0181"> <h3 class="title" id="CD011286-sec-0181">Agreements and disagreements with other studies or reviews</h3> <p>Meta‐analyses (<a href="./references#CD011286-bbs2-0057" title="BressaGM . S‐adenosyl‐l‐methionine (SAMe) as antidepressant: meta‐analysis of clinical studies. Acta Neurologica Scandinavica. Supplementum1994;154:7‐14. ">Bressa 1994</a>; <a href="./references#CD011286-bbs2-0082" title="HardyM , CoulterI , MortonSC , FavreauJ , VenuturupalliS , ChiappelliF , et al. S‐adenosyl‐L‐methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment Number 64. Rockville, MD: Agency for Healthcare Research and QualityOctober 2002. ">Hardy 2002</a>) and systematic reviews (<a href="./references#CD011286-bbs2-0061" title="CarpenterDJ . St. John's wort and S‐adenosyl methionine as &quot;natural&quot; alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?. Alternative Medicine Review2011;16(1):17‐39. ">Carpenter 2011</a>; <a href="./references#CD011286-bbs2-0092" title="MischoulonD , FavaM . Role of S‐adenosyl L‐methionine in the treatment of depression: a review of the evidence. American Journal of Clinical Nutrition2002;76:1158S‐61S. ">Mischoulon 2002</a>; <a href="./references#CD011286-bbs2-0101" title="PapakostasGI , AlpertJE , FavaM . S‐adenosyl methionine in the treatment of depression: a comprehensive review of the literature. Current Psychiatry Reports2003;5:460‐6. ">Papakostas 2003</a>; <a href="./references#CD011286-bbs2-0118" title="WilliamsAL , GirardC , JuiD , SabinaA , KatzDl . S‐adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and Investigative Medicine2005;28:132‐9. ">Williams 2005</a>) have consistently concluded that SAMe is effective for treating depression, with an efficacy superior to placebo and equivalent to the conventional antidepressants. Further, when used in combination with conventional antidepressants, it has been reported that SAMe seems to have the potential to enhance response or limit adverse effects, by allowing lower doses of the conventional antidepressant to be prescribed (<a href="./references#CD011286-bbs2-0109" title="SarrisJ , KavanaghDJ , ByrneG . Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. Journal of Psychiatric Research2010;44:32‐41. ">Sarris 2010</a>). </p> <p>In our review, we found that the efficacy of SAMe for the treatment of depression was not different from TCA and SSRI antidepressants and higher than placebo as an adjunctive treatment, though the comparisons with SSRI antidepressants and placebo as an adjunctive treatment included only one study. In contrast to the findings of other reviews, we did not demonstrate superior efficacy of SAMe in comparison with placebo in monotherapy. In our review, this analysis was undermined by a high level of heterogeneity and included only two studies. </p> <p>With regard to acceptability, SAMe has generally reported to be safe and well‐tolerated with a more favourable adverse effect profile than conventional antidepressants (<a href="./references#CD011286-bbs2-0061" title="CarpenterDJ . St. John's wort and S‐adenosyl methionine as &quot;natural&quot; alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?. Alternative Medicine Review2011;16(1):17‐39. ">Carpenter 2011</a>; <a href="./references#CD011286-bbs2-0082" title="HardyM , CoulterI , MortonSC , FavreauJ , VenuturupalliS , ChiappelliF , et al. S‐adenosyl‐L‐methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment Number 64. Rockville, MD: Agency for Healthcare Research and QualityOctober 2002. ">Hardy 2002</a>; <a href="./references#CD011286-bbs2-0105" title="RambaldiA , GluudC . S‐adenosyl‐L‐methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD002235.pub2] ">Rambaldi 2006</a>). In our review, SAM‐e was not found to be different from either placebo or established antidepressants. </p> <p>SAMe has been reported to be associated (in rare instances) with induction of mania (<a href="./references#CD011286-bbs2-0060" title="CarneyMW , CharyTK , BottiglieriT , ReynoldsEH . The switch mechanism and the bipolar/unipolar dichotomy. British Journal of Psychiatry1989;154:48‐51. ">Carney 1989</a>; <a href="./references#CD011286-bbs2-0061" title="CarpenterDJ . St. John's wort and S‐adenosyl methionine as &quot;natural&quot; alternatives to conventional antidepressants in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit?. Alternative Medicine Review2011;16(1):17‐39. ">Carpenter 2011</a>; <a href="./references#CD011286-bbs2-0080" title="GörenJL , StollAL , DamicoKE , SarmientoIA , CohenBM . Bioavailability and lack of toxicity of S‐adenosyl‐L‐methionine (SAMe) in humans. Pharmacotherapy2004;24(11):1501‐7. ">Gören 2004</a>; <a href="./references#CD011286-bbs2-0089" title="LipinskiJF , CohenBM , FrankenburgF , TohenM , WaternauxC , AltesmanR , JonesB . Open trial of S‐adenosylmethionine for treatment of depression. American Journal of Psychiatry1984;141:448‐50. ">Lipinski 1984</a>) ‐ similarly to conventional antidepressants. Two studies in our review reported one participant each who presented with manic/hypomanic symptoms in the SAMe arm. </p> <p>Where our findings differ from results of previous reviews, it could be considered that the quality and the methodological rigour of many of the individual studies included in the previous reviews is questionable. Most of these studies were older, had a heterogeneous population of participants with a diagnosis not necessarily restricted to major depression. Many of the studies exhibited methodological flaws, had a small sample size and a short duration of treatment. Often they include data from 'completer' data‐sets only and exclude participants dropping out for any reason from the efficacy analysis. </p> <p>We strictly adhered to the inclusion criteria of our protocol, aiming to improve the quality of the body of the evidence (<a href="./references#CD011286-bbs2-0119" title="GaliziaI , OldaniL , MacritchieK , AmariE , DougallD , JonesTN , et al. S‐adenosyl methionine (SAM‐e) for depression in adults. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011286] ">Galizia 2014</a>). This was probably the reason we have included fewer studies in this review than other reviews. Nevertheless, we met the same limitations of the previous reviews. Some studies were methodologically dated, lacked information on methodological key issues, had an inadequate sample size, included data from completers participants only, did not report data in an extractable way or a combination of these. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011286-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD011286-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011286-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011286-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement)." data-id="CD011286-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects." data-id="CD011286-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study." data-id="CD011286-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania." data-id="CD011286-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 7 Acceptability. Participants experiencing specific adverse effects: headache." data-id="CD011286-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 7 Acceptability. Participants experiencing specific adverse effects: headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 8 Acceptability. Participants experiencing specific adverse effects: flatulence." data-id="CD011286-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 8 Acceptability. Participants experiencing specific adverse effects: flatulence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 9 Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 S‐adenosyl methionine versus placebo as monotherapy, Outcome 9 Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects." data-id="CD011286-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 5 Acceptability. Participants experiencing troublesome adverse effects of any nature." data-id="CD011286-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 5 Acceptability. Participants experiencing troublesome adverse effects of any nature. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania." data-id="CD011286-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 7 Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 7 Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects." data-id="CD011286-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study." data-id="CD011286-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 6 Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 6 Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 2 Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects." data-id="CD011286-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 3 Acceptability. Participants dropping out of treatment during study period because of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study." data-id="CD011286-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 6 Acceptability. Participants experiencing specific adverse effects: headache." data-id="CD011286-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 6 Acceptability. Participants experiencing specific adverse effects: headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 7 Acceptability. Participants experiencing specific adverse effects: diarrhoea." data-id="CD011286-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 7 Acceptability. Participants experiencing specific adverse effects: diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 8 Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI, Outcome 8 Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 1 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement)." data-id="CD011286-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 1 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 2 Sensitivity analysis for imputation of dichotomous data (assumption: 'best‐case' scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 2 Sensitivity analysis for imputation of dichotomous data (assumption: 'best‐case' scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 3 Sensitivity analysis for the imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 3 Sensitivity analysis for the imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 4 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 4 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 5 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 5 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 6 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 6 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 7 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy, Outcome 7 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 1 Subgroup analysis (oral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 1 Subgroup analysis (oral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 2 Subgroup analysis (parenteral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 2 Subgroup analysis (parenteral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 3 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 3 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 4 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 4 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 5 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects." data-id="CD011286-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 5 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 6 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects." data-id="CD011286-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 6 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 7 Subgroup analysis (oral administration of SAMe). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 7 Subgroup analysis (oral administration of SAMe). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 8 Subgroup analysis (parenteral administration of SAMe). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 8 Subgroup analysis (parenteral administration of SAMe). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 9 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature." data-id="CD011286-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 9 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 10 Subgroup analysis (oral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature." data-id="CD011286-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 10 Subgroup analysis (oral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 11 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 11 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 12 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects." data-id="CD011286-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 12 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 13 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 13 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 14 Sensitivity analysis for imputation of dichotomous data (assumption: 'best‐case' scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 14 Sensitivity analysis for imputation of dichotomous data (assumption: 'best‐case' scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 15 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 15 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 16 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 16 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 17 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 17 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 18 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 18 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 19 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants experiencing troublesome adverse effects of any nature." data-id="CD011286-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 19 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants experiencing troublesome adverse effects of any nature. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 20 Sensitivity analysis (excluding De Vanna 1992). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.20</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 20 Sensitivity analysis (excluding De Vanna 1992). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 21 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Acceptability. Participants dropping out of treatment during study period for any reason." data-id="CD011286-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.21</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 21 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Acceptability. Participants dropping out of treatment during study period for any reason. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-006-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-006-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 22 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment." data-id="CD011286-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.22</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy, Outcome 22 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-006-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Sensitivity analysis. S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Sensitivity analysis. S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy, Outcome 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011286-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/urn:x-wiley:14651858:media:CD011286:CD011286-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_t/tCD011286-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sensitivity analysis. S‐adenosyl methionine versus placebo as adjunctive treatment, Outcome 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)." data-id="CD011286-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Sensitivity analysis. S‐adenosyl methionine versus placebo as adjunctive treatment, Outcome 1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/media/CDSR/CD011286/image_n/nCD011286-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011286-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> SAMe as monotherapy </p> <p><b>Comparison:</b> placebo as monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo as monotherapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe as monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative SMD indicates greater improvement in the SAMe group<br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe groups was<br/> <b>0.54 standard deviations greater</b> (1.54 lower to 0.46 higher) indicating more improvement. However, this was not statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.54 (95% CI ‐1.54 to 0.46)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> <br/> (0.61 to 1.29) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (22 to 47) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 3 to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.77</b> <br/> (0.51 to 6.13) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 100</b> <br/> (11 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants achieving remission</b> <br/> Depression rating scale score within the normal range at the end of the study </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.69</b> <br/> (0.85 to 3.36) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>124<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> <br/> (14 to 56) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of inconsistency caused by high level of heterogeneity (I<sup>2</sup> = 72%; P = 0.06), related to the different duration of the trials and sample size (3 weeks, 18 participants for <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a>; 12 weeks, 124 participants for <a href="./references#CD011286-bbs2-0007" title="FavaM . A double‐blind, placebo‐controlled study of the alternative therapy S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. clinicaltrials.gov/show/NCT00101452 (accessed 3 August 2016). [http://clinicaltrials.gov/show/NCT00101452] GerbargPL , MuskinPR , BottiglieriT , BrownRP . Failed studies should not be used to malign good treatments [NCT00101452]. Journal of Clinical Psychiatry2014;75(11):e1328. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM . Dr. Mischoulon and colleagues reply [NCT00101452]. Comment on failed studies should not be used to malign good treatments. Journal of Clinical Psychiatry2014;75(11):e1328‐9. MischoulonD , PriceLH , CarpenterLL , TyrkaAR , PapakostasGI , FavaM , et al. A double‐blind, randomized, placebo‐controlled clinical trial of S‐adenosyl‐l‐methionine (SAMe) versus escitalopram in major depressive disorder. Journal of Clinical Psychiatry2014;75(4):370‐6. SarrisJ , PapakostasGI , VitoloO , FavaM , MischoulonD . S‐adenosylmethionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of Affective Disorders2014;164:76‐81. SarrisJ , PriceLH , CarpenterLL , TyrkaAR , NgCH , PapakostasGI , et al. Is S‐adenosyl methionine (SAMe) for depression only effective in males? A re‐analysis of data from a randomized controlled trial. Pharmacopsychiatry2015;48(4‐5):141‐4. ">Mischoulon 2014</a>).<br/> <sup>2</sup> downgraded one point because of imprecision caused by small sample size, fewer than 400.<br/> <sup>3</sup> downgraded one point because of imprecision caused by a 95% confidence interval that included no effect and the upper and lower confidence limit crosses an effect size of 0.5 in either direction.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300.<br/> <sup>5</sup> downgraded one point because of imprecision caused by a 95% confidence interval that includes both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%).<br/> <sup>6</sup> The two studies showed a non‐significant heterogeneity (I<sup>2</sup> = 49%; P = 0.16). This was due to the <a href="./references#CD011286-bbs2-0006" title="KaganBL , SultzerL , RosenlichtN , GernerRH . Oral S‐adenosylmethionine in depression: a randomized, double‐blind, placebo‐controlled trial. American Journal of Psychiatry1990;147(5):591‐5. ">Kagan 1990</a> study where the number of responder was bigger in the SAMe arm than the placebo arm, but it was not statistically significant (RR 4.80, 95% CI 0.72 to 32.15; P = 0.11). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to placebo as monotherapy for depression in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011286-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to tricyclic antidepressant agent as monotherapy for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine compared to tricyclic antidepressant agent as monotherapy for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> SAMe as monotherapy </p> <p><b>Comparison:</b> TCA as monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe vs. TCA as monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative SMD indicates greater improvement in the SAMe group<br/> Follow‐up: 2 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe group was<br/> <b>0.04 standard deviations greater</b> (0.34 lower to 0.27 higher), indicating more improvement. However, this was not statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.04 (95% CI ‐0.34 to 0.27)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 2 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.61</b> <br/> (0.28 to 1.31) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>78<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 100</b> <br/> (9 to 44) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 100</b> <br/> (7 to 35) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 2 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.14</b> <br/> (0.83 to 1.56) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very</b> </p> <p><b>low</b><sup>5,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 100</b> <br/> (42 to 79) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>39 per 100</b> <br/> (28 to 54) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportions of participants achieving remission</b> <br/> Depression rating scale score within the normal range at the end of the study </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> <br/> Follow‐up: 4 to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.68</b> <br/> (0.52 to 0.88) </p> <p>statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>604<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> <br/> (25 to 43) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (24 to 41) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SMD:</b> standardised mean difference; <b>TCA:</b> tricyclic antidepressant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; three studies were at unclear risk of selection, performance, detection and attrition bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>).<br/> <sup>2</sup> downgraded one point because of inconsistency caused by significant heterogeneity between the studies (I<sup>2</sup> = 57%; P = 0.07). It was due to one study that favoured SAMe over the active antidepressant (imipramine) (<a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a>). The different result of the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study could be due to its shorter duration (two weeks) and to the fact that the therapeutic actions of imipramine usually are not immediate, but often delayed by two to four weeks. This could suggest a more rapid onset of action of the SAMe. Also, the doses and routes of administration of SAMe among the studies were heterogeneous. However, when subgroup analysis was conducted separating data regarding oral and parenteral administration of SAMe, the outcome was not affected.<br/> <sup>3</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study was at high risk of attrition bias and at unclear risk of selection bias; the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study was at unclear risk of selection, performance, detection and attrition bias.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300.<br/> <sup>5</sup> downgraded one point because of imprecision caused by a 95% confidence interval that includes both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%).<br/> <sup>6</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; the <a href="./references#CD011286-bbs2-0002" title="BellKM , CarreonD , PlonL , BunneyWeJr , PotkinSG . Oral S‐adenosylmethionine in the treatment of depression: a double‐blind comparison with desipramine. Study report. BioResearch File1990:53‐4. BellKM , PotkinSG , CarreonD , PlonL . S‐adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurologica Scandinavica1994;154(Suppl 1):15‐8. ">Bell 1994</a> study was at high risk of attrition bias and at unclear risk of selection bias; two studies were at unclear risk of selection, performance, detection and attrition bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>).<br/> <sup>7</sup> downgraded one point because of inconsistency caused by significant heterogeneity among the studies (I<sup>2</sup> = 58%, P = 0.07). It could be caused by the different durations of the treatment. Then, the studies differed in terms of antidepressants compared to the intervention, but it did not explain the heterogeneity. Also, the doses and routes of administration of SAMe among the studies were heterogeneous. However, when we conducted subgroup analysis separating data regarding oral and parenteral administration of SAMe, the outcome was not affected.<br/> <sup>8</sup> downgraded one point because of risk of bias: the three studies were at unclear risk of selection, performance, detection and attrition bias (<a href="./references#CD011286-bbs2-0003" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicentrum studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc3: multicentre, controlled efficacy and safety trial of oral S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . Multicentre, controlled efficacy and safety trial of S‐adenosyl‐methionine (SAMe) vs oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. Delle ChiaieR , PancheriR , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2000:NR499. ">Delle Chiaie 2000a</a>; <a href="./references#CD011286-bbs2-0004" title="Delle ChiaieR , PancheriP , ScapicchioP . Efficacy and tolerability of oral and intramuscular s‐adenosyl‐l‐methionine 1,4‐butanedisulfunate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. American Journal of Clinical Nutrition2002;76(5):1172‐6. Delle ChiaieR , PancheriP , ScapicchioP . Mc4: multicentre, controlled efficacy and safety trial of intramuscular S‐adenosylmethionine (SAMe) versus oral imipramine in the treatment of depression. International Journal of Neuropsychopharmacology2000;3(Suppl 1):S230. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10, New Orleans. 2001:NR499. Delle ChiaieR , PancheriP , ScapicchioP . S‐adenosyl‐methionine (SAMe) in major depression: two multicenter trials versus imipramine. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, PA. 2002. PancheriP , ScapicchioP , Delle ChiaieR . A double‐blind, randomized parallel‐group, efficacy and safety study of intramuscular S‐adenosyl‐L‐methionine 1,4‐butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. International Journal of Neuropsychopharmacology2002;5(4):287‐94. ">Delle Chiaie 2000b</a>; <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a>).<br/> <sup>9</sup> downgraded one point because of risk of bias: the <a href="./references#CD011286-bbs2-0001" title="BellKM , PlonL , BunneyWEJr , PotkinSG . S‐adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry1988;145(9):1110‐14. PotkinSG , BellK , PlonL , BunneyWEJr . Rapid antidepressant response with SAMe. A double‐study. Alabama Journal of Medical Sciences1988;25(3):313‐6. ">Bell 1988</a> study was at unclear risk of selection, performance and detection bias; the <a href="./references#CD011286-bbs2-0005" title="DeVannaM , RigamontiR . Oral S‐adenosyl‐l‐methionine in depression. Current Therapeutic Research, Clinical and Experimental1992;52(3):478‐85. ">De Vanna 1992</a> study was at unclear risk of selection, performance, detection and attrition bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to tricyclic antidepressant agent as monotherapy for depression in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011286-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to SSRI antidepressant agent as monotherapy for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine compared to SSRI antidepressant agent as monotherapy for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> SAMe as monotherapy </p> <p><b>Comparison:</b> SSRI antidepressant agent as monotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe vs. SSRI antidepressant agent as monotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative MD indicates greater improvement in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe group was<br/> <b>0.12 standard deviations lower</b> (2.75 lower to 2.99 higher), indicating less improvement. However, this was not statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.12 (95% CI ‐2.75 to 2.99)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/> (0.57 to 1.16) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (31 to 62) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 100</b> <br/> (31 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.06</b> <br/> (0.66 to 1.7) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> <br/> (22 to 58) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> <br/> (22 to 58) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Proportions of participants achieving remission</b> <br/> depression rating scale score within the normal range at the end of the study </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.58 to 1.77) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> <br/> (16 to 49) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 100</b> <br/> (16 to 49) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SSRI:</b> selective serotonin reuptake inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of imprecision caused by small sample size, fewer than 400.<br/> <sup>2</sup> downgraded one point because of imprecision caused by a 95% confidence interval that included no effect and the upper and lower confidence limit crossed an effect size of 0.5 in either direction.<br/> <sup>3</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a 95% confidence interval that includes both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">S‐adenosyl methionine as monotherapy compared to SSRI antidepressant agent as monotherapy for depression in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011286-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">S‐adenosyl methionine as adjunctive treatment compared to placebo as add‐on to SSRI for depression in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>S‐adenosyl methionine as adjunctive treatment compared to placebo as add‐on for depression in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with depression<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> SAMe as adjunctive treatment to SSRI<br/> <b>Comparison:</b> placebo as adjunctive treatment to SSRI </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo as add‐on</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SAMe as adjunctive treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Efficacy. Change in scores from baseline to end of treatment on the depression rating scale</b> <br/> A larger negative MD indicates greater improvement in the SAMe group<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in scores from baseline to end of treatment on the depression rating scale in the SAMe group was<br/> <b>3.9 greater</b> (6.93 to 0.87 lower), indicating more improvement. This was statistically significant </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐3.90 (‐6.93 to ‐0.87)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acceptability</b> <br/> Participants dropping out of treatment during the study period for any reason<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.7</b> <br/> (0.31 to 1.56) </p> <p>not statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> <br/> (9 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants responding to treatment</b> <br/> ≥ 50% reduction in depression score from baseline to end of treatment. </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.62</b> <br/> (1.17 to 5.83) </p> <p>statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 100</b> <br/> (21 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proportions of participants achieving remission</b> <br/> depression rating scale score within the normal range at the end of the study. </p> <p>A larger RR indicates greater response to treatment in the SAMe group<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.05</b> <br/> (1.11 to 8.39) </p> <p>statistically significant</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> <br/> (13 to 99) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acceptability. Participants experiencing troublesome adverse effects of any nature</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SAMe:</b> S‐adenosyl methionine; <b>SSRI:</b> selective serotonin reuptake inhibitor. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one point because of imprecision caused by small sample size, fewer than 400.<br/> <sup>2</sup> downgraded one point because of indirectness caused by a population restricted to SSRI non‐responders<br/> <sup>3</sup> downgraded one point because of imprecision caused by a 95% confidence interval that included both no effect and appreciable benefit and appreciable harm (the threshold for 'appreciable benefit' or 'appreciable harm' was a relative risk reduction (RRR) or relative risk increase (RRI) greater than 25%.<br/> <sup>4</sup> downgraded one point because of imprecision caused by a total number of events that was fewer than 300. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">S‐adenosyl methionine as adjunctive treatment compared to placebo as add‐on to SSRI for depression in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/full#CD011286-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">S‐adenosyl methionine versus placebo as monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.54, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acceptability. Participants dropping out of treatment during study period because of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.16, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.51, 6.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acceptability. Participants experiencing specific adverse effects: headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Acceptability. Participants experiencing specific adverse effects: flatulence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.60, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">S‐adenosyl methionine versus placebo as monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.34, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.34, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.28, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.29, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 vs. desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.14, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acceptability. Participants dropping out of treatment during study period because of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.20, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.20, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.83, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.81, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 vs. desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.74, 12.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Acceptability. Participants experiencing troublesome adverse effects of any nature <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Acceptability. Participants experiencing specific adverse effects: mania or hypomania <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.17, 5.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.17, 5.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acceptability. Participants dropping out of treatment during study period because of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acceptability. Participants dropping out of treatment during study period because of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Acceptability. Participants experiencing specific adverse effects: headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Acceptability. Participants experiencing specific adverse effects: diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">S‐adenosyl methionine versus placebo as adjunctive treatment to SSRI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of treatment on the depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.50, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sensitivity analysis for imputation of dichotomous data (assumption: 'best‐case' scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.84, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Sensitivity analysis for the imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐1.53, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analyses. S‐adenosyl methionine versus placebo as monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subgroup analysis (oral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.17, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.17, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Subgroup analysis (parenteral administration of SAMe). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.68, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.68, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.20, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 vs. desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.14, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out of treatment during study period because of adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Subgroup analysis (oral administration of SAMe). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.44, 4.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.73, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 vs. desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.74, 12.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis (parenteral administration of SAMe). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.66, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.66, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis (oral administration of SAMe). Acceptability. Participants experiencing troublesome adverse effects of any nature <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.50, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.50, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Subgroup analysis (oral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Subgroup analysis (parenteral administration of SAMe). Acceptability. Participants dropping out for any reasons other than adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Sensitivity analysis for imputation of continuous efficacy data (assumption: missing participants had same mean change as other participants). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.43, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.43, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sensitivity analysis for imputation of dichotomous data (assumption: 'best‐case' scenario). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.82, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.81, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 vs. desipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.51, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.43, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.43, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.83, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.83, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.29, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.29, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Sensitivity analysis (excluding studies with high levels of missing data). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Sensitivity analysis (excluding studies with high levels of missing data). Acceptability. Participants experiencing troublesome adverse effects of any nature <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Sensitivity analysis (excluding De Vanna 1992). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.44, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.44, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Acceptability. Participants dropping out of treatment during study period for any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.29, 2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.29, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Sensitivity analysis (excluding Bell 1994, as at high risk of bias). Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.81, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 vs. imipramine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.81, 1.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity and subgroup analyses. S‐adenosyl methionine versus tricyclic antidepressant agent as monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analysis. S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 vs. escitalopram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analysis. S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011286-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis. S‐adenosyl methionine versus placebo as adjunctive treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Sensitivity analysis for imputation of SD (using correlation coefficient of 0.4). Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis. S‐adenosyl methionine versus placebo as adjunctive treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011286.pub2/references#CD011286-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011286.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011286-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011286-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD011286-note-0002">日本語</a> </li> <li class="section-language"> <a class="" href="ru#CD011286-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011286\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011286\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011286\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011286\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011286\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WcPhDegp&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011286.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011286.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011286.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011286.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011286.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726390419"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011286.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726390423"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011286.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e927c981d9368',t:'MTc0MDcyNjM5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 